Biopharmaceuticals Market Share Report, Growth Analysis 2028
[Research Report] The biopharmaceuticals market is expected to grow from US$ 3,29,966.22 million in 2022 to US$ 7,00,873.94 million by 2028; it is expected to grow at a CAGR of 13.4% from 2022 to 2028.
Rising applications in cancer therapeutics and potential to treat rare diseases are a few factors driving the biopharmaceuticals market growth.
According to the National Cancer Institute report, cancer is among the leading cause of death globally. For instance, in 2018, there were 18.1 million new cancer cases and 9.5 million cancer-related deaths worldwide. By 2040, the new cancer cases are expected to rise to 29.5 million, with cancer-related deaths to 16.4 million. The US Department of Health and Human Services report states that the rate of new lung and bronchus cancer cases is 52.0 per 100,000 men and women annually. The estimated number of new lung and bronchus cancer cases was 236,740 in 2022, i.e., 12.3% of all new cancer cases. Biopharmaceuticals present new opportunities for gaining control over such a high incidence of cancer. Based on the understanding of underlying biological mechanisms and the role of patients' immune systems in fighting cancer, biopharmaceutical researchers are producing new medicines responsible for treating different types of cancer. These range from CAR-T cell therapy to immune checkpoint inhibitors and personalized medicines, targeting the genetic flaws translating into a specific cancer condition. A report by the Pharmaceutical Research and Manufacturers of America (PhRMA) reveals that six CAR-T therapies have been approved by the US Food and Drug Administration (FDA) for treating a wide range of cancer types, including pediatric cancer cases. Additionally, the PhRMA report reveals that other therapeutic approaches, such as mRNA with the potential to transform a wide range of cancers, have gained approvals. For instance, in February 2023, mRNA-4157/V940, an investigational personalized mRNA cancer vaccine by Moderna, Inc. and Merck, was recognized as a breakthrough therapy, in combination with KEYTRUDA, by the USFDA. Further, more than 1,300 medicines and vaccines for treating various cancers are currently in clinical trials or are awaiting FDA approval. These involve immunotherapies (monoclonal antibodies and CAR-T), gene editing for target cancer, oncolytic viral therapies, and antibody–drug conjugates (ADCs) targeting specific cancer cells without harming normal cells.
Thus, the rising incidence of cancers globally results in the demand for safe, effective, and efficient diagnostic systems, such as biopharmaceuticals.
Customize Research To Suit Your Requirement
We can optimize and tailor the analysis and scope which is unmet through our standard offerings. This flexibility will help you gain the exact information needed for your business planning and decision making.
Biopharmaceuticals Market: Strategic Insights
Market Size Value in US$ 3,29,966.22 million in 2022 Market Size Value by US$ 7,00,873.94 million by 2028 Growth rate CAGR of 13.4% from 2022 to 2028 Forecast Period 2022-2028 Base Year 2022
Mrinal
Have a question?
Mrinal will walk you through a 15-minute call to present the report’s content and answer all queries if you have any.
Speak to Analyst
Customize Research To Suit Your Requirement
We can optimize and tailor the analysis and scope which is unmet through our standard offerings. This flexibility will help you gain the exact information needed for your business planning and decision making.
Biopharmaceuticals Market: Strategic Insights
| Market Size Value in | US$ 3,29,966.22 million in 2022 |
| Market Size Value by | US$ 7,00,873.94 million by 2028 |
| Growth rate | CAGR of 13.4% from 2022 to 2028 |
| Forecast Period | 2022-2028 |
| Base Year | 2022 |
Mrinal
Have a question?
Mrinal will walk you through a 15-minute call to present the report’s content and answer all queries if you have any.
Speak to Analyst
Application Segment Insight
Based on application, the biopharmaceuticals market is segmented into oncology, inflammatory & infectious disease, autoimmune disorders, metabolic disorders, hormonal disorders & growth failure, cardiovascular diseases, neurological diseases, and others. The oncology segment held the largest share of the market in 2022. However, the inflammatory and infectious diseases segment is expected to register the highest CAGR during the forecast period. According to the National Institute of Health (NIH) report, cancer is a complex invasive genetic disease causing significant mortality globally. For example, protein-based biopharmaceuticals have significantly extended the lives of millions of cancer patients. Further, various top companies entered a research collaboration for developing novel therapeutics-based targeted protein-based technology for cancer treatment. For instance, in April 2022, Ubix Therapeutics announced a collaboration with SK Biopharmaceuticals to develop new compounds and medicines through Ubix's Degraducer technology for cancer treatment. Such aforementioned factors are responsible for the segment growth, thereby contributing to the market growth of biopharmaceuticals during the forecast period.
North America is likely to continue its dominance in the biopharmaceuticals market during the forecast period. The US held the largest market share in this region in 2022. According to The International Trade Administration report, the US is the largest market for biopharmaceuticals accounting for approximately a third of the global biopharmaceutical market with pioneers in biopharmaceutical R&D. Also, the economic impact of the biopharmaceutical industry in the US economy is substantial. In 2018, over US$ 17 billion in biopharmaceutical exports were from most foreign-owned firms operating in the US. Moreover, in the same year, these majority foreign-owned firms spent ~US$ 20 billion on R&D.
On the other hand, Asia Pacific is expected to witness lucrative growth over the forecast period. This is due to China's biopharmaceutical industry undergoing a tremendous shift evolving from a generics-focused to a thriving innovation hub. Additionally, promoting industrialization and growing application of novel drugs and high-end medical devices and techniques are a few factors responsible for the growth of the biopharmaceuticals market in China.
According to the Information Technology & Innovation Foundation (ITIF) report, China has made considerable progress in matching the US in innovation. Furthermore, with an average of 36 indicators, China has cut the bridging gap with the US by a competitive factor of 1.5 to the present (the competitive factors are identified and evaluated for relative importance to achieve the firm's strategic goals). Additionally, a decade ago, China was 80% behind the US; however, in 2022, it was at 50% owing to dramatic progress in innovation, technology influx, and favorable state-directed industrial and trade policies. Also, new product approvals for treating rare diseases further influence the market growth in China. For instance, in March 2022, CANbridge Pharmaceuticals Inc., a pioneer China-based biopharmaceutical company, announced that the Taiwan Food and Drug Administration (TFDA) had accepted the New Drug Application/Orphan Drug Registration (NDA/ODR) for "CAN108 [maralixibat oral solution (LIVMARLI TM)]" intended for treating cholestatic pruritus among patients suffering from Alagille syndrome (ALGS) for 1 year of age and older.
Product Type Insights
Based on product type, the biopharmaceuticals market is segmented into monooclonal antibodies, recombinant vaccines, conventional vaccine, recombinant growth factors, purified proteins, recombinant proteins, recombinant hormones, recombinant enzymes, cell and gene therapies, cytokines/interferon/interleukins, and others (mRNA-based therapeutics, etc.). The monoclonal antibodies segment held the largest market share in 2022 and is anticipated to register a significant CAGR during the forecast period. Monoclonal antibodies (mABs) are at the forefront of the biological products market and will continue to lead resource investment in the biopharmaceutical market by providing innovative therapeutic solutions intended for immune oncology and immunotherapy. mABs treat multiple diseases such as cancer, organ transplant rejection, inflammatory and autoimmune diseases, allergies, infections, COVID-19, osteoporosis, eye disorders, migraines, high cholesterol, and nervous system disorders. There are many different mABs used to treat cancer. They work in different ways to kill or stop cancer cells from growing. They all have names that include "mab" at the end of their generic name—for example, trastuzumab (Herceptin) and rituximab (Mabthera). Approvals of monoclonal antibody therapies by the US Food and Drug Administration (FDA) have increased since the first drug containing monoclonal antibodies was approved for humans. A major benefit of monoclonal antibodies is that they have successfully been used to manufacture drugs to treat certain diseases, such as some cancers. Another benefit of monoclonal antibodies is that they are more accurate than other treatments. This improves effectiveness and can reduce some side effects. The quality of the monoclonal antibodies is standard for all production batches, which is important for both therapeutic use and diagnostics. Such aforementioned factors are responsible for the segment growth, thereby fueling the biopharmaceuticals market during the forecast period.
Companies operating in the biopharmaceuticals market adopt the product innovation strategy to meet the evolving customer demands worldwide, permitting them to maintain their brand name in the global market.
Biopharmaceuticals Market Report Scope
Biopharmaceuticals Market – Segmentation
Based on product type, the biopharmaceuticals market is segmented into monoclonal antibodies, recombinant vaccines, conventional vaccines, recombinant growth factors, purified proteins, recombinant proteins, recombinant hormones, recombinant enzymes, cell & gene therapies, cytokines/interferon/interleukins, and others. Based on application, the market is segmented into oncology, inflammatory & infectious disease, autoimmune disorders, metabolic disorders, hormonal disorders & growth failure, cardiovascular diseases, neurological diseases, and others. Based on geography, the market is primarily segmented into North America, Europe, Asia Pacific (APAC), the Middle East & Africa (MEA), and South & Central America. The market in North America is further segmented into the US, Canada, and Mexico. The European biopharmaceuticals market is sub-segmented into France, Germany, the UK, Spain, Italy, and the Rest of Europe. The market in Asia Pacific is further segmented into China, India, Japan, Australia, South Korea, and the Rest of APAC. The biopharmaceuticals market in the MEA is sub-segmented into Saudi Arabia, the UAE, South Africa, and the Rest of MEA. The market in South & Central America is further segmented into Brazil, Argentina, and the Rest of South & Central America.
A few of the leading companies operating in the biopharmaceuticals market are Amgen Inc., AbbVie Inc., Eli Lilly and Co, Bristol-Myers Squibb Co, Johnson & Johnson, Thermo Fisher Scientific Inc., AGC Biologics AS, Lonza Group AG, WuXi Biologics Inc., and Boehringer Ingelheim International GmbH.
Report Coverage
Revenue forecast, Company Analysis, Industry landscape, Growth factors, and Trends
Segment Covered
Product Type, and Application
Regional Scope
North America, Europe, Asia Pacific, Middle East & Africa, South & Central America
Country Scope
Argentina, Australia, Brazil, Canada, China, France, Germany, India, Italy, Japan, Mexico, Saudi Arabia, South Africa, South Korea, Spain, United Arab Emirates, United Kingdom, United States
Frequently Asked Questions
Global biopharmaceuticals market is segmented by region into North America, Europe, Asia Pacific, the Middle East & Africa, and South & Central America. North America held the largest market share of the biopharmaceuticals market in 2022. With several North American market players focusing on research and development activities in the field of imaging technology, the regional market for biopharmaceuticals market is likely to propel in North America region during the forecast period.
Eli Lilly and Co and Amgen Inc are the top two companies that hold huge market shares in the biopharmaceuticals market.
The biopharmaceuticals market majorly consists of the players such Amgen Inc, AbbVie Inc, Eli Lilly and Co, Bristol-Myers Squibb Co, Johnson & Johnson, Thermo Fisher Scientific Inc, AGC Biologics AS, Lonza Group AG, WuXi Biologics Inc, Boehringer Ingelheim International GmbH amongst others.
The CAGR value of the biopharmaceuticals market during the forecasted period of 2022-2028 is 13.4%.
The monoclonal antibodies segment held the largest share of the market in the global biopharmaceuticals market and held the market share of 48.42% in 2022.
Biopharmaceuticals are complex medicines that are manufactured by extracting proteins and nucleic acids directly from biological sources using biotechnology. Most biopharmaceuticals are pharmaceutical products that are made from living organisms; transgenic organisms are genetically modified plants and animals, and this process is used to produce biopharmaceuticals; nevertheless, it is a controversial technology still in the testing phase.
Key factors that are driving the growth of this market are rising application in cancer therapeutics and potential to treat rare diseases are expected to boost the market growth for the biopharmaceuticals over the years.
1. Introduction
1.1 Scope of the Study
1.2 The Insight Partners Research Report Guidance
1.3 Market Segmentation
1.3.1 Global Biopharmaceuticals Market – by Product Type
1.3.2 Global Biopharmaceuticals Market – by Application
1.3.3 Global Biopharmaceuticals Market – by Geography
2. Biopharmaceuticals Market – Key Takeaways
3. Research Methodology
3.1 Coverage
3.2 Secondary Research
3.3 Primary Research
4. Biopharmaceuticals Market – Market Landscape
4.1 Overview
4.2 PEST Analysis
4.2.1 North America PEST Analysis
4.2.2 Europe PEST Analysis
4.2.3 Asia Pacific PEST Analysis
4.2.4 Middle East & Africa PEST Analysis
4.2.5 South & Central America PEST Analysis
4.3 Expert’s Opinion
5. Biopharmaceuticals Market – Key Market Dynamics
5.1 Market Drivers
5.1.1 Rising Application in Cancer Therapeutics
5.1.2 Potential to Treat Rare Diseases
5.2 Market Restraints
5.2.1 High Cost of Manufacturing Infrastructure
5.3 Market Opportunities
5.3.1 Accelerated Clinical Trials
5.4 Future Trends
5.4.1 Contract Manufacturing of Biopharmaceuticals
5.5 Impact Analysis
6. Biopharmaceuticals Market – Global Analysis
6.1 Global Biopharmaceuticals Market Revenue Forecast and Analysis
6.2 Global Biopharmaceuticals Market, by Geography – Forecast and Analysis
6.3 Market Positioning of Key Players
7. Global Biopharmaceuticals Market – Revenue and Forecast to 2028 – by Product Type
7.1 Overview
7.2 Biopharmaceuticals Market Revenue Share, by Product Type 2021 & 2028 (%)
7.3 Monoclonal Antibodies
7.3.1 Overview
7.3.2 Monoclonal Antibodies: Biopharmaceuticals Market – Revenue and Forecast to 2028 (US$ Million)
7.4 Recombinant Vaccines
7.4.1 Overview
7.4.2 Recombinant Vaccines: Biopharmaceuticals Market – Revenue and Forecast to 2028 (US$ Million)
7.4.2.1 Cancer Vaccine
7.4.2.1.1 Overview
7.4.2.1.2 Cancer Vaccine: Biopharmaceuticals Market – Revenue and Forecast to 2028 (US$ Million)
7.4.2.2 Malaria Vaccine
7.4.2.2.1 Overview
7.4.2.2.2 Malaria Vaccine: Biopharmaceuticals Market – Revenue and Forecast to 2028 (US$ Million)
7.4.2.3 Ebola Vaccine
7.4.2.3.1 Overview
7.4.2.3.2 Ebola Vaccine: Biopharmaceuticals Market – Revenue and Forecast to 2028 (US$ Million)
7.4.2.4 Hepatitis-B Vaccine
7.4.2.4.1 Overview
7.4.2.4.2 Hepatitis-B Vaccine: Biopharmaceuticals Market – Revenue and Forecast to 2028 (US$ Million)
7.4.2.5 Tetanus Vaccine
7.4.2.5.1 Overview
7.4.2.5.2 Tetanus Vaccine: Biopharmaceuticals Market – Revenue and Forecast to 2028 (US$ Million)
7.4.2.6 Diphtheria Vaccine
7.4.2.6.1 Overview
7.4.2.6.2 Diphtheria Vaccine: Biopharmaceuticals Market – Revenue and Forecast to 2028 (US$ Million)
7.4.2.7 Cholera Vaccine
7.4.2.7.1 Overview
7.4.2.7.2 Cholera Vaccine: Biopharmaceuticals Market – Revenue and Forecast to 2028 (US$ Million)
7.4.2.8 Others
7.4.2.8.1 Overview
7.4.2.8.2 Others: Biopharmaceuticals Market – Revenue and Forecast to 2028 (US$ Million)
7.5 Conventional Vaccines
7.5.1 Overview
7.5.2 Conventional Vaccines: Biopharmaceuticals Market – Revenue and Forecast to 2028 (US$ Million)
7.5.2.1 Polio Vaccine
7.5.2.1.1 Overview
7.5.2.1.2 Polio Vaccine: Biopharmaceuticals Market – Revenue and Forecast to 2028 (US$ Million)
7.5.2.2 Pox Vaccine
7.5.2.2.1 Overview
7.5.2.2.2 Pox Vaccine: Biopharmaceuticals Market – Revenue and Forecast to 2028 (US$ Million)
7.5.2.3 Other Conventional Vaccine
7.5.2.3.1 Overview
7.5.2.3.2 Other Conventional Vaccine: Biopharmaceuticals Market – Revenue and Forecast to 2028 (US$ Million)
7.6 Recombinant Growth Factors
7.6.1 Overview
7.6.2 Recombinant Growth Factors: Biopharmaceuticals Market – Revenue and Forecast to 2028 (US$ Million)
7.6.2.1 Erythropoietin
7.6.2.1.1 Overview
7.6.2.1.2 Erythropoietin: Biopharmaceuticals Market – Revenue and Forecast to 2028 (US$ Million)
7.6.2.2 Granulocyte Colony Stimulating Factor
7.6.2.2.1 Overview
7.6.2.2.2 Granulocyte Colony Stimulating Factor: Biopharmaceuticals Market – Revenue and Forecast to 2028 (US$ Million)
7.7 Purified Proteins
7.7.1 Overview
7.7.2 Purified Proteins: Biopharmaceuticals Market – Revenue and Forecast to 2028 (US$ Million)
7.7.2.1 Leukemia Inhibitory Factor (LIF)
7.7.2.1.1 Overview
7.7.2.1.2 Leukemia Inhibitory Factor (LIF): Biopharmaceuticals Market – Revenue and Forecast to 2028 (US$ Million)
7.7.2.2 P53 Protein
7.7.2.2.1 Overview
7.7.2.2.2 P53 Protein: Biopharmaceuticals Market – Revenue and Forecast to 2028 (US$ Million)
7.7.2.3 P38 Protein
7.7.2.3.1 Overview
7.7.2.3.2 P38 Protein: Biopharmaceuticals Market – Revenue and Forecast to 2028 (US$ Million)
7.7.2.4 Other Purified Proteins
7.7.2.4.1 Overview
7.7.2.4.2 Other Purified Proteins: Biopharmaceuticals Market – Revenue and Forecast to 2028 (US$ Million)
7.8 Recombinant Proteins
7.8.1 Overview
7.8.2 Recombinant Proteins: Biopharmaceuticals Market – Revenue and Forecast to 2028 (US$ Million)
7.8.2.1 Serum Albumin
7.8.2.1.1 Overview
7.8.2.1.2 Serum Albumin: Biopharmaceuticals Market – Revenue and Forecast to 2028 (US$ Million)
7.8.2.2 Amyloid Protein
7.8.2.2.1 Overview
7.8.2.2.2 Amyloid Protein: Biopharmaceuticals Market – Revenue and Forecast to 2028 (US$ Million)
7.8.2.3 Defensin
7.8.2.3.1 Overview
7.8.2.3.2 Defensin: Biopharmaceuticals Market – Revenue and Forecast to 2028 (US$ Million)
7.8.2.4 Transferrin
7.8.2.4.1 Overview
7.8.2.4.2 Transferrin: Biopharmaceuticals Market – Revenue and Forecast to 2028 (US$ Million)
7.9 Recombinant Hormones
7.9.1 Overview
7.9.2 Recombinant Hormones: Biopharmaceuticals Market – Revenue and Forecast to 2028 (US$ Million)
7.9.2.1 Recombinant Human Growth Hormones
7.9.2.1.1 Overview
7.9.2.1.2 Recombinant Human Growth Hormones: Biopharmaceuticals Market – Revenue and Forecast to 2028 (US$ Million)
7.9.2.2 Recombinant Insulin
7.9.2.2.1 Overview
7.9.2.2.2 Recombinant Insulin: Biopharmaceuticals Market – Revenue and Forecast to 2028 (US$ Million)
7.9.2.3 Other Recombinant Hormones
7.9.2.3.1 Overview
7.9.2.3.2 Other Recombinant Hormones: Biopharmaceuticals Market – Revenue and Forecast to 2028 (US$ Million)
7.10 Recombinant Enzymes
7.10.1 Overview
7.10.2 Recombinant Enzymes: Biopharmaceuticals Market – Revenue and Forecast to 2028 (US$ Million)
7.10.2.1 Enterokinase
7.10.2.1.1 Overview
7.10.2.1.2 Enterokinase: Biopharmaceuticals Market – Revenue and Forecast to 2028 (US$ Million)
7.10.2.2 Cyclase
7.10.2.2.1 Overview
7.10.2.2.2 Cyclase: Biopharmaceuticals Market – Revenue and Forecast to 2028 (US$ Million)
7.10.2.3 Caspase
7.10.2.3.1 Overview
7.10.2.3.2 Caspase: Biopharmaceuticals Market – Revenue and Forecast to 2028 (US$ Million)
7.10.2.4 Cathepsin
7.10.2.4.1 Overview
7.10.2.4.2 Cathepsin: Biopharmaceuticals Market – Revenue and Forecast to 2028 (US$ Million)
7.11 Cell and Gene Therapies
7.11.1 Overview
7.11.2 Cell and Gene Therapies: Biopharmaceuticals Market – Revenue and Forecast to 2028 (US$ Million)
7.11.2.1 Allogenic Products
7.11.2.1.1 Overview
7.11.2.1.2 Allogenic Products: Biopharmaceuticals Market – Revenue and Forecast to 2028 (US$ Million)
7.11.2.2 Autologous Products
7.11.2.2.1 Overview
7.11.2.2.2 Autologous Products: Biopharmaceuticals Market – Revenue and Forecast to 2028 (US$ Million)
7.11.2.3 Acellular Products
7.11.2.3.1 Overview
7.11.2.3.2 Acellular Products: Biopharmaceuticals Market – Revenue and Forecast to 2028 (US$ Million)
7.12 Cytokines/Interferon/Interleukins
7.12.1 Overview
7.12.2 Cytokines/Interferon/Interleukins: Biopharmaceuticals Market – Revenue and Forecast to 2028 (US$ Million)
7.13 Others (mRNA Based Therapeutics, etc.)
7.13.1 Overview
7.13.2 Others (mRNA Based Therapeutics, etc.): Biopharmaceuticals Market – Revenue and Forecast to 2028 (US$ Million)
8. Global Biopharmaceuticals Market Analysis and Forecasts to 2028 – by Application
8.1 Overview
8.2 Global Biopharmaceuticals Market, by Application 2021 & 2028 (%)
8.3 Oncology
8.3.1 Overview
8.3.2 Oncology: Biopharmaceuticals Market – Revenue and Forecast to 2028 (US$ Million)
8.4 Inflammatory and Infectious Diseases
8.4.1 Overview
8.4.2 Inflammatory and Infectious Diseases: Biopharmaceuticals Market – Revenue and Forecast to 2028 (US$ Million)
8.5 Autoimmune Disorders
8.5.1 Overview
8.5.2 Autoimmune Disorders: Biopharmaceuticals Market – Revenue and Forecast to 2028 (US$ Million)
8.6 Metabolic Disorders
8.6.1 Overview
8.6.2 Metabolic Disorders: Biopharmaceuticals Market – Revenue and Forecast to 2028 (US$ Million)
8.7 Hormonal Disorders and Growth Failure
8.7.1 Overview
8.7.2 Hormonal Disorders and Growth Failure: Biopharmaceuticals Market – Revenue and Forecast to 2028 (US$ Million)
8.8 Cardiovascular Diseases
8.8.1 Overview
8.8.2 Cardiovascular Diseases: Biopharmaceuticals Market – Revenue and Forecast to 2028 (US$ Million)
8.9 Neurological Diseases
8.9.1 Overview
8.9.2 Neurological Diseases: Biopharmaceuticals Market – Revenue and Forecast to 2028 (US$ Million)
8.10 Other Therapeutic Applications
8.10.1 Overview
8.10.2 Other Therapeutic Applications: Biopharmaceuticals Market – Revenue and Forecast to 2028 (US$ Million)
9. Biopharmaceuticals Market – Revenue and Forecast to 2028 – Geographic Analysis
9.1 North America: Biopharmaceuticals Market
9.1.1 Overview
9.1.2 North America: Biopharmaceuticals Market – Revenue and Forecast to 2028 (US$ Million)
9.1.3 North America: Biopharmaceuticals Market, by Product Type, 2019–2028 (US$ Million)
9.1.3.1 North America: Biopharmaceuticals Market, by Recombinant Vaccines, 2019–2028 (US$ Million)
9.1.3.2 North America: Biopharmaceuticals Market, by Conventional Vaccines, 2019–2028 (US$ Million)
9.1.3.3 North America: Biopharmaceuticals Market, by Recombinant Growth Factors, 2019–2028 (US$ Million)
9.1.3.4 North America: Biopharmaceuticals Market, by Purified Proteins, 2019–2028 (US$ Million)
9.1.3.5 North America: Biopharmaceuticals Market, by Recombinant Proteins, 2019–2028 (US$ Million)
9.1.3.6 North America: Biopharmaceuticals Market, by Recombinant Hormones, 2019–2028 (US$ Million)
9.1.3.7 North America: Biopharmaceuticals Market, by Recombinant Enzymes, 2019–2028 (US$ Million)
9.1.3.8 North America: Biopharmaceuticals Market, by Cell & Gene Therapies, 2019–2028 (US$ Million)
9.1.4 North America: Biopharmaceuticals Market, by Application, 2019–2028 (US$ Million)
9.1.4.1 United States: Biopharmaceuticals Market – Revenue and Forecast to 2028 (US$ Million)
9.1.4.1.1 United States: Biopharmaceuticals Market, by Product Type, 2019–2028 (US$ Million)
9.1.4.1.1.1 United States: Biopharmaceuticals Market, by Recombinant Vaccines, 2019–2028 (US$ Million)
9.1.4.1.1.2 United States: Biopharmaceuticals Market, by Conventional Vaccines, 2019–2028 (US$ Million)
9.1.4.1.1.3 United States: Biopharmaceuticals Market, by Recombinant Growth Factors, 2019–2028 (US$ Million)
9.1.4.1.1.4 United States: Biopharmaceuticals Market, by Purified Proteins, 2019–2028 (US$ Million)
9.1.4.1.1.5 United States: Biopharmaceuticals Market, by Recombinant Proteins, 2019–2028 (US$ Million)
9.1.4.1.1.6 United States: Biopharmaceuticals Market, by Recombinant Hormones, 2019–2028 (US$ Million)
9.1.4.1.1.7 United States: Biopharmaceuticals Market, by Recombinant Enzymes, 2019–2028 (US$ Million)
9.1.4.1.1.8 United States: Biopharmaceuticals Market, by Cell & Gene Therapies, 2019–2028 (US$ Million)
9.1.4.1.2 United States: Biopharmaceuticals Market, by Application, 2019–2028 (US$ Million)
9.1.4.2 Canada: Biopharmaceuticals Market – Revenue and Forecast to 2028 (US$ Million)
9.1.4.2.1 Canada: Biopharmaceuticals Market, by Product Type, 2019–2028 (US$ Million)
9.1.4.2.1.1 Canada: Biopharmaceuticals Market, by Recombinant Vaccines, 2019–2028 (US$ Million)
9.1.4.2.1.2 Canada: Biopharmaceuticals Market, by Conventional Vaccines, 2019–2028 (US$ Million)
9.1.4.2.1.3 Canada: Biopharmaceuticals Market, by Recombinant Growth Factors, 2019–2028 (US$ Million)
9.1.4.2.1.4 Canada: Biopharmaceuticals Market, by Purified Proteins, 2019–2028 (US$ Million)
9.1.4.2.1.5 Canada: Biopharmaceuticals Market, by Recombinant Proteins, 2019–2028 (US$ Million)
9.1.4.2.1.6 Canada: Biopharmaceuticals Market, by Recombinant Hormones, 2019–2028 (US$ Million)
9.1.4.2.1.7 Canada: Biopharmaceuticals Market, by Recombinant Enzymes, 2019–2028 (US$ Million)
9.1.4.2.1.8 Canada: Biopharmaceuticals Market, by Cell & Gene Therapies, 2019–2028 (US$ Million)
9.1.4.2.2 Canada: Biopharmaceuticals Market, by Application, 2019–2028 (US$ Million)
9.1.4.3 Mexico: Biopharmaceuticals Market – Revenue and Forecast to 2028 (US$ Million)
9.1.4.3.1 Mexico: Biopharmaceuticals Market, by Product Type, 2019–2028 (US$ Million)
9.1.4.3.1.1 Mexico: Biopharmaceuticals Market, by Recombinant Vaccines, 2019–2028 (US$ Million)
9.1.4.3.1.2 Mexico: Biopharmaceuticals Market, by Conventional Vaccines, 2019–2028 (US$ Million)
9.1.4.3.1.3 Mexico: Biopharmaceuticals Market, by Recombinant Growth Factors, 2019–2028 (US$ Million)
9.1.4.3.1.4 Mexico: Biopharmaceuticals Market, by Purified Proteins, 2019–2028 (US$ Million)
9.1.4.3.1.5 Mexico: Biopharmaceuticals Market, by Recombinant Proteins, 2019–2028 (US$ Million)
9.1.4.3.1.6 Mexico: Biopharmaceuticals Market, by Recombinant Hormones, 2019–2028 (US$ Million)
9.1.4.3.1.7 Mexico: Biopharmaceuticals Market, by Recombinant Enzymes, 2019–2028 (US$ Million)
9.1.4.3.1.8 Mexico: Biopharmaceuticals Market, by Cell & Gene Therapies, 2019–2028 (US$ Million)
9.1.4.3.2 Mexico: Biopharmaceuticals Market, by Application, 2019–2028 (US$ Million)
9.2 Europe: Biopharmaceuticals Market
9.2.1 Overview
9.2.2 Europe: Biopharmaceuticals Market – Revenue and Forecast to 2028 (US$ Million)
9.2.3 Europe: Biopharmaceuticals Market, by Product Type, 2019–2028 (US$ Million)
9.2.3.1 Europe: Biopharmaceuticals Market, by Recombinant Vaccines, 2019–2028 (US$ Million)
9.2.3.2 Europe: Biopharmaceuticals Market, by Conventional Vaccines, 2019–2028 (US$ Million)
9.2.3.3 Europe: Biopharmaceuticals Market, by Recombinant Growth Factors, 2019–2028 (US$ Million)
9.2.3.4 Europe: Biopharmaceuticals Market, by Purified Proteins, 2019–2028 (US$ Million)
9.2.3.5 Europe: Biopharmaceuticals Market, by Recombinant Proteins, 2019–2028 (US$ Million)
9.2.3.6 Europe: Biopharmaceuticals Market, by Recombinant Hormones, 2019–2028 (US$ Million)
9.2.3.7 Europe: Biopharmaceuticals Market, by Recombinant Enzymes, 2019–2028 (US$ Million)
9.2.3.8 Europe: Biopharmaceuticals Market, by Cell & Gene Therapies, 2019–2028 (US$ Million)
9.2.4 Europe: Biopharmaceuticals Market, by Application, 2019–2028 (US$ Million)
9.2.5 Europe: Biopharmaceuticals Market, by Country, 2021 & 2028 (%)
9.2.5.1 United Kingdom: Biopharmaceuticals Market – Revenue and Forecast to 2028 (US$ Million)
9.2.5.1.1 United Kingdom: Biopharmaceuticals Market, by Product Type, 2019–2028 (US$ Million)
9.2.5.1.1.1 United Kingdom: Biopharmaceuticals Market, by Recombinant Vaccines, 2019–2028 (US$ Million)
9.2.5.1.1.2 United Kingdom: Biopharmaceuticals Market, by Conventional Vaccines, 2019–2028 (US$ Million)
9.2.5.1.1.3 United Kingdom: Biopharmaceuticals Market, by Recombinant Growth Factors, 2019–2028 (US$ Million)
9.2.5.1.1.4 United Kingdom: Biopharmaceuticals Market, by Purified Proteins, 2019–2028 (US$ Million)
9.2.5.1.1.5 United Kingdom: Biopharmaceuticals Market, by Recombinant Proteins, 2019–2028 (US$ Million)
9.2.5.1.1.6 United Kingdom: Biopharmaceuticals Market, by Recombinant Hormones, 2019–2028 (US$ Million)
9.2.5.1.1.7 United Kingdom: Biopharmaceuticals Market, by Recombinant Enzymes, 2019–2028 (US$ Million)
9.2.5.1.1.8 United Kingdom: Biopharmaceuticals Market, by Cell & Gene Therapies, 2019–2028 (US$ Million)
9.2.5.1.2 United Kingdom: Biopharmaceuticals Market, by Application, 2019–2028 (US$ Million)
9.2.5.2 Germany: Biopharmaceuticals Market – Revenue and Forecast to 2028 (US$ Million)
9.2.5.2.1 Germany: Biopharmaceuticals Market, by Product Type, 2019–2028 (US$ Million)
9.2.5.2.1.1 Germany: Biopharmaceuticals Market, by Recombinant Vaccines, 2019–2028 (US$ Million)
9.2.5.2.1.2 Germany: Biopharmaceuticals Market, by Conventional Vaccines, 2019–2028 (US$ Million)
9.2.5.2.1.3 Germany: Biopharmaceuticals Market, by Recombinant Growth Factors, 2019–2028 (US$ Million)
9.2.5.2.1.4 Germany: Biopharmaceuticals Market, by Purified Proteins, 2019–2028 (US$ Million)
9.2.5.2.1.5 Germany: Biopharmaceuticals Market, by Recombinant Proteins, 2019–2028 (US$ Million)
9.2.5.2.1.6 Germany: Biopharmaceuticals Market, by Recombinant Hormones, 2019–2028 (US$ Million)
9.2.5.2.1.7 Germany: Biopharmaceuticals Market, by Recombinant Enzymes, 2019–2028 (US$ Million)
9.2.5.2.1.8 Germany: Biopharmaceuticals Market, by Cell & Gene Therapies, 2019–2028 (US$ Million)
9.2.5.2.2 Germany: Biopharmaceuticals Market, by Application, 2019–2028 (US$ Million)
9.2.5.3 France: Biopharmaceuticals Market – Revenue and Forecast to 2028 (US$ Million)
9.2.5.3.1 France: Biopharmaceuticals Market, by Product Type, 2019–2028 (US$ Million)
9.2.5.3.1.1 France: Biopharmaceuticals Market, by Recombinant Vaccines, 2019–2028 (US$ Million)
9.2.5.3.1.2 France: Biopharmaceuticals Market, by Conventional Vaccines, 2019–2028 (US$ Million)
9.2.5.3.1.3 France: Biopharmaceuticals Market, by Recombinant Growth Factors, 2019–2028 (US$ Million)
9.2.5.3.1.4 France: Biopharmaceuticals Market, by Purified Proteins, 2019–2028 (US$ Million)
9.2.5.3.1.5 France: Biopharmaceuticals Market, by Recombinant Proteins, 2019–2028 (US$ Million)
9.2.5.3.1.6 France: Biopharmaceuticals Market, by Recombinant Hormones, 2019–2028 (US$ Million)
9.2.5.3.1.7 France: Biopharmaceuticals Market, by Recombinant Enzymes, 2019–2028 (US$ Million)
9.2.5.3.1.8 France: Biopharmaceuticals Market, by Cell & Gene Therapies, 2019–2028 (US$ Million)
9.2.5.3.2 France: Biopharmaceuticals Market, by Application, 2019–2028 (US$ Million)
9.2.5.4 Italy: Biopharmaceuticals Market – Revenue and Forecast to 2028 (US$ Million)
9.2.5.4.1 Italy: Biopharmaceuticals Market, by Product Type, 2019–2028 (US$ Million)
9.2.5.4.1.1 Italy: Biopharmaceuticals Market, by Recombinant Vaccines, 2019–2028 (US$ Million)
9.2.5.4.1.2 Italy: Biopharmaceuticals Market, by Conventional Vaccines, 2019–2028 (US$ Million)
9.2.5.4.1.3 Italy: Biopharmaceuticals Market, by Recombinant Growth Factors, 2019–2028 (US$ Million)
9.2.5.4.1.4 Italy: Biopharmaceuticals Market, by Purified Proteins, 2019–2028 (US$ Million)
9.2.5.4.1.5 Italy: Biopharmaceuticals Market, by Recombinant Proteins, 2019–2028 (US$ Million)
9.2.5.4.1.6 Italy: Biopharmaceuticals Market, by Recombinant Hormones, 2019–2028 (US$ Million)
9.2.5.4.1.7 Italy: Biopharmaceuticals Market, by Recombinant Enzymes, 2019–2028 (US$ Million)
9.2.5.4.1.8 Italy: Biopharmaceuticals Market, by Cell & Gene Therapies, 2019–2028 (US$ Million)
9.2.5.4.2 Italy: Biopharmaceuticals Market, by Application, 2019–2028 (US$ Million)
9.2.5.5 Spain: Biopharmaceuticals Market – Revenue and Forecast to 2028 (US$ Million)
9.2.5.5.1 Spain: Biopharmaceuticals Market, by Product Type, 2019–2028 (US$ Million)
9.2.5.5.1.1 Spain: Biopharmaceuticals Market, by Recombinant Vaccines, 2019–2028 (US$ Million)
9.2.5.5.1.2 Spain: Biopharmaceuticals Market, by Conventional Vaccines, 2019–2028 (US$ Million)
9.2.5.5.1.3 Spain: Biopharmaceuticals Market, by Recombinant Growth Factors, 2019–2028 (US$ Million)
9.2.5.5.1.4 Spain: Biopharmaceuticals Market, by Purified Proteins, 2019–2028 (US$ Million)
9.2.5.5.1.5 Spain: Biopharmaceuticals Market, by Recombinant Proteins, 2019–2028 (US$ Million)
9.2.5.5.1.6 Spain: Biopharmaceuticals Market, by Recombinant Hormones, 2019–2028 (US$ Million)
9.2.5.5.1.7 Spain: Biopharmaceuticals Market, by Recombinant Enzymes, 2019–2028 (US$ Million)
9.2.5.5.1.8 Spain: Biopharmaceuticals Market, by Cell & Gene Therapies, 2019–2028 (US$ Million)
9.2.5.5.2 Spain: Biopharmaceuticals Market, by Application, 2019–2028 (US$ Million)
9.2.5.6 Rest of Europe: Biopharmaceuticals Market – Revenue and Forecast to 2028 (US$ Million)
9.2.5.6.1 Rest of Europe: Biopharmaceuticals Market, by Product Type, 2019–2028 (US$ Million)
9.2.5.6.1.1 Rest of Europe: Biopharmaceuticals Market, by Recombinant Vaccines, 2019–2028 (US$ Million)
9.2.5.6.1.2 Rest of Europe: Biopharmaceuticals Market, by Conventional Vaccines, 2019–2028 (US$ Million)
9.2.5.6.1.3 Rest of Europe: Biopharmaceuticals Market, by Recombinant Growth Factors, 2019–2028 (US$ Million)
9.2.5.6.1.4 Rest of Europe: Biopharmaceuticals Market, by Purified Proteins, 2019–2028 (US$ Million)
9.2.5.6.1.5 Rest of Europe: Biopharmaceuticals Market, by Recombinant Proteins, 2019–2028 (US$ Million)
9.2.5.6.1.6 Rest of Europe: Biopharmaceuticals Market, by Recombinant Hormones, 2019–2028 (US$ Million)
9.2.5.6.1.7 Rest of Europe: Biopharmaceuticals Market, by Recombinant Enzymes, 2019–2028 (US$ Million)
9.2.5.6.1.8 Rest of Europe: Biopharmaceuticals Market, by Cell & Gene Therapies, 2019–2028 (US$ Million)
9.2.5.6.2 Rest of Europe: Biopharmaceuticals Market, by Application, 2019–2028 (US$ Million)
9.3 Asia Pacific: Biopharmaceuticals Market
9.3.1 Overview
9.3.2 Asia Pacific: Biopharmaceuticals Market – Revenue and Forecast to 2028 (US$ Million)
9.3.3 Asia Pacific: Biopharmaceuticals Market, by Product Type, 2019–2028 (US$ Million)
9.3.3.1 Asia Pacific: Biopharmaceuticals Market, by Recombinant Vaccines, 2019–2028 (US$ Million)
9.3.3.2 Asia Pacific: Biopharmaceuticals Market, by Conventional Vaccines, 2019–2028 (US$ Million)
9.3.3.3 Asia Pacific: Biopharmaceuticals Market, by Recombinant Growth Factors, 2019–2028 (US$ Million)
9.3.3.4 Asia Pacific: Biopharmaceuticals Market, by Purified Proteins, 2019–2028 (US$ Million)
9.3.3.5 Asia Pacific: Biopharmaceuticals Market, by Recombinant Proteins, 2019–2028 (US$ Million)
9.3.3.6 Asia Pacific: Biopharmaceuticals Market, by Recombinant Hormones, 2019–2028 (US$ Million)
9.3.3.7 Asia Pacific: Biopharmaceuticals Market, by Recombinant Enzymes, 2019–2028 (US$ Million)
9.3.3.8 Asia Pacific: Biopharmaceuticals Market, by Cell & Gene Therapies, 2019–2028 (US$ Million)
9.3.4 Asia Pacific: Biopharmaceuticals Market, by Application, 2019–2028 (US$ Million)
9.3.5 Asia Pacific: Biopharmaceuticals Market, by Country, 2021 & 2028 (%)
9.3.5.1 China: Biopharmaceuticals Market – Revenue and Forecast to 2028 (US$ Million)
9.3.5.1.1 China: Biopharmaceuticals Market, by Product Type, 2019–2028 (US$ Million)
9.3.5.1.1.1 China: Biopharmaceuticals Market, by Recombinant Vaccines, 2019–2028 (US$ Million)
9.3.5.1.1.2 China: Biopharmaceuticals Market, by Conventional Vaccines, 2019–2028 (US$ Million)
9.3.5.1.1.3 China: Biopharmaceuticals Market, by Recombinant Growth Factors, 2019–2028 (US$ Million)
9.3.5.1.1.4 China: Biopharmaceuticals Market, by Purified Proteins, 2019–2028 (US$ Million)
9.3.5.1.1.5 China: Biopharmaceuticals Market, by Recombinant Proteins, 2019–2028 (US$ Million)
9.3.5.1.1.6 China: Biopharmaceuticals Market, by Recombinant Hormones, 2019–2028 (US$ Million)
9.3.5.1.1.7 China: Biopharmaceuticals Market, by Recombinant Enzymes, 2019–2028 (US$ Million)
9.3.5.1.1.8 China: Biopharmaceuticals Market, by Cell & Gene Therapies, 2019–2028 (US$ Million)
9.3.5.1.2 China: Biopharmaceuticals Market, by Application, 2019–2028 (US$ Million)
9.3.5.2 Japan: Biopharmaceuticals Market – Revenue and Forecast to 2028 (US$ Million)
9.3.5.2.1 Japan: Biopharmaceuticals Market, by Product Type, 2019–2028 (US$ Million)
9.3.5.2.1.1 Japan: Biopharmaceuticals Market, by Recombinant Vaccines, 2019–2028 (US$ Million)
9.3.5.2.1.2 Japan: Biopharmaceuticals Market, by Conventional Vaccines, 2019–2028 (US$ Million)
9.3.5.2.1.3 Japan: Biopharmaceuticals Market, by Recombinant Growth Factors, 2019–2028 (US$ Million)
9.3.5.2.1.4 Japan: Biopharmaceuticals Market, by Purified Proteins, 2019–2028 (US$ Million)
9.3.5.2.1.5 Japan: Biopharmaceuticals Market, by Recombinant Proteins, 2019–2028 (US$ Million)
9.3.5.2.1.6 Japan: Biopharmaceuticals Market, by Recombinant Hormones, 2019–2028 (US$ Million)
9.3.5.2.1.7 Japan: Biopharmaceuticals Market, by Recombinant Enzymes, 2019–2028 (US$ Million)
9.3.5.2.1.8 Japan: Biopharmaceuticals Market, by Cell & Gene Therapies, 2019–2028 (US$ Million)
9.3.5.2.2 Japan: Biopharmaceuticals Market, by Application, 2019–2028 (US$ Million)
9.3.5.3 India: Biopharmaceuticals Market – Revenue and Forecast to 2028 (US$ Million)
9.3.5.3.1 India: Biopharmaceuticals Market, by Product Type, 2019–2028 (US$ Million)
9.3.5.3.1.1 India: Biopharmaceuticals Market, by Recombinant Vaccines, 2019–2028 (US$ Million)
9.3.5.3.1.2 India: Biopharmaceuticals Market, by Conventional Vaccines, 2019–2028 (US$ Million)
9.3.5.3.1.3 India: Biopharmaceuticals Market, by Recombinant Growth Factors, 2019–2028 (US$ Million)
9.3.5.3.1.4 India: Biopharmaceuticals Market, by Purified Proteins, 2019–2028 (US$ Million)
9.3.5.3.1.5 India: Biopharmaceuticals Market, by Recombinant Proteins, 2019–2028 (US$ Million)
9.3.5.3.1.6 India: Biopharmaceuticals Market, by Recombinant Hormones, 2019–2028 (US$ Million)
9.3.5.3.1.7 India: Biopharmaceuticals Market, by Recombinant Enzymes, 2019–2028 (US$ Million)
9.3.5.3.1.8 India: Biopharmaceuticals Market, by Cell & Gene Therapies, 2019–2028 (US$ Million)
9.3.5.3.2 India: Biopharmaceuticals Market, by Application, 2019–2028 (US$ Million)
9.3.5.4 South Korea: Biopharmaceuticals Market – Revenue and Forecast to 2028 (US$ Million)
9.3.5.4.1 South Korea: Biopharmaceuticals Market, by Product Type, 2019–2028 (US$ Million)
9.3.5.4.1.1 South Korea: Biopharmaceuticals Market, by Recombinant Vaccines, 2019–2028 (US$ Million)
9.3.5.4.1.2 South Korea: Biopharmaceuticals Market, by Conventional Vaccines, 2019–2028 (US$ Million)
9.3.5.4.1.3 South Korea: Biopharmaceuticals Market, by Recombinant Growth Factors, 2019–2028 (US$ Million)
9.3.5.4.1.4 South Korea: Biopharmaceuticals Market, by Purified Proteins, 2019–2028 (US$ Million)
9.3.5.4.1.5 South Korea: Biopharmaceuticals Market, by Recombinant Proteins, 2019–2028 (US$ Million)
9.3.5.4.1.6 South Korea: Biopharmaceuticals Market, by Recombinant Hormones, 2019–2028 (US$ Million)
9.3.5.4.1.7 South Korea: Biopharmaceuticals Market, by Recombinant Enzymes, 2019–2028 (US$ Million)
9.3.5.4.1.8 South Korea: Biopharmaceuticals Market, by Cell & Gene Therapies, 2019–2028 (US$ Million)
9.3.5.4.2 South Korea: Biopharmaceuticals Market, by Application, 2019–2028 (US$ Million)
9.3.5.5 Australia: Biopharmaceuticals Market – Revenue and Forecast to 2028 (US$ Million)
9.3.5.5.1 Australia: Biopharmaceuticals Market, by Product Type, 2019–2028 (US$ Million)
9.3.5.5.1.1 Australia: Biopharmaceuticals Market, by Recombinant Vaccines, 2019–2028 (US$ Million)
9.3.5.5.1.2 Australia: Biopharmaceuticals Market, by Conventional Vaccines, 2019–2028 (US$ Million)
9.3.5.5.1.3 Australia: Biopharmaceuticals Market, by Recombinant Growth Factors, 2019–2028 (US$ Million)
9.3.5.5.1.4 Australia: Biopharmaceuticals Market, by Purified Proteins, 2019–2028 (US$ Million)
9.3.5.5.1.5 Australia: Biopharmaceuticals Market, by Recombinant Proteins, 2019–2028 (US$ Million)
9.3.5.5.1.6 Australia: Biopharmaceuticals Market, by Recombinant Hormones, 2019–2028 (US$ Million)
9.3.5.5.1.7 Australia: Biopharmaceuticals Market, by Recombinant Enzymes, 2019–2028 (US$ Million)
9.3.5.5.1.8 Australia: Biopharmaceuticals Market, by Cell & Gene Therapies, 2019–2028 (US$ Million)
9.3.5.5.2 Australia: Biopharmaceuticals Market, by Application, 2019–2028 (US$ Million)
9.3.5.6 Rest of Asia Pacific: Biopharmaceuticals Market – Revenue and Forecast to 2028 (US$ Million)
9.3.5.6.1 Rest of Asia Pacific: Biopharmaceuticals Market, by Product Type, 2019–2028 (US$ Million)
9.3.5.6.1.1 Rest of Asia Pacific: Biopharmaceuticals Market, by Recombinant Vaccines, 2019–2028 (US$ Million)
9.3.5.6.1.2 Rest of Asia Pacific: Biopharmaceuticals Market, by Conventional Vaccines, 2019–2028 (US$ Million)
9.3.5.6.1.3 Rest of Asia Pacific: Biopharmaceuticals Market, by Recombinant Growth Factors, 2019–2028 (US$ Million)
9.3.5.6.1.4 Rest of Asia Pacific: Biopharmaceuticals Market, by Purified Proteins, 2019–2028 (US$ Million)
9.3.5.6.1.5 Rest of Asia Pacific: Biopharmaceuticals Market, by Recombinant Proteins, 2019–2028 (US$ Million)
9.3.5.6.1.6 Rest of Asia Pacific: Biopharmaceuticals Market, by Recombinant Hormones, 2019–2028 (US$ Million)
9.3.5.6.1.7 Rest of Asia Pacific: Biopharmaceuticals Market, by Recombinant Enzymes, 2019–2028 (US$ Million)
9.3.5.6.1.8 Rest of Asia Pacific: Biopharmaceuticals Market, by Cell & Gene Therapies, 2019–2028 (US$ Million)
9.3.5.6.2 Rest of Asia Pacific: Biopharmaceuticals Market, by Application, 2019–2028 (US$ Million)
9.4 Middle East & Africa Biopharmaceuticals Market
9.4.1 Overview
9.4.2 Middle East & Africa: Biopharmaceuticals Market – Revenue and Forecast to 2028 (US$ Million)
9.4.3 Middle East & Africa: Biopharmaceuticals Market, by Product Type, 2019–2028 (US$ Million)
9.4.3.1 Middle East & Africa: Biopharmaceuticals Market, by Recombinant Vaccines, 2019–2028 (US$ Million)
9.4.3.2 Middle East & Africa: Biopharmaceuticals Market, by Conventional Vaccines, 2019–2028 (US$ Million)
9.4.3.3 Middle East & Africa: Biopharmaceuticals Market, by Recombinant Growth Factors, 2019–2028 (US$ Million)
9.4.3.4 Middle East & Africa: Biopharmaceuticals Market, by Purified Proteins, 2019–2028 (US$ Million)
9.4.3.5 Middle East & Africa: Biopharmaceuticals Market, by Recombinant Proteins, 2019–2028 (US$ Million)
9.4.3.6 Middle East & Africa: Biopharmaceuticals Market, by Recombinant Hormones, 2019–2028 (US$ Million)
9.4.3.7 Middle East & Africa: Biopharmaceuticals Market, by Recombinant Enzymes, 2019–2028 (US$ Million)
9.4.3.8 Middle East & Africa: Biopharmaceuticals Market, by Cell & Gene Therapies, 2019–2028 (US$ Million)
9.4.4 Middle East & Africa: Biopharmaceuticals Market, by Application, 2019–2028 (US$ Million)
9.4.5 Middle East & Africa: Biopharmaceuticals Market, by Country, 2021 & 2028 (%)
9.4.5.1 UAE: Biopharmaceuticals Market – Revenue and Forecast to 2028 (US$ Million)
9.4.5.1.1 UAE: Biopharmaceuticals Market, by Product Type, 2019–2028 (US$ Million)
9.4.5.1.1.1 UAE: Biopharmaceuticals Market, by Recombinant Vaccines, 2019–2028 (US$ Million)
9.4.5.1.1.2 UAE: Biopharmaceuticals Market, by Conventional Vaccines, 2019–2028 (US$ Million)
9.4.5.1.1.3 UAE: Biopharmaceuticals Market, by Recombinant Growth Factors, 2019–2028 (US$ Million)
9.4.5.1.1.4 UAE: Biopharmaceuticals Market, by Purified Proteins, 2019–2028 (US$ Million)
9.4.5.1.1.5 UAE: Biopharmaceuticals Market, by Recombinant Proteins, 2019–2028 (US$ Million)
9.4.5.1.1.6 UAE: Biopharmaceuticals Market, by Recombinant Hormones, 2019–2028 (US$ Million)
9.4.5.1.1.7 UAE: Biopharmaceuticals Market, by Recombinant Enzymes, 2019–2028 (US$ Million)
9.4.5.1.1.8 UAE: Biopharmaceuticals Market, by Cell & Gene Therapies, 2019–2028 (US$ Million)
9.4.5.1.2 UAE: Biopharmaceuticals Market, by Application, 2019–2028 (US$ Million)
9.4.5.2 Saudi Arabia: Biopharmaceuticals Market – Revenue and Forecast to 2028 (US$ Million)
9.4.5.2.1 Saudi Arabia: Biopharmaceuticals Market, by Product Type, 2019–2028 (US$ Million)
9.4.5.2.1.1 Saudi Arabia: Biopharmaceuticals Market, by Recombinant Vaccines, 2019–2028 (US$ Million)
9.4.5.2.1.2 Saudi Arabia: Biopharmaceuticals Market, by Conventional Vaccines, 2019–2028 (US$ Million)
9.4.5.2.1.3 Saudi Arabia: Biopharmaceuticals Market, by Recombinant Growth Factors, 2019–2028 (US$ Million)
9.4.5.2.1.4 Saudi Arabia: Biopharmaceuticals Market, by Purified Proteins, 2019–2028 (US$ Million)
9.4.5.2.1.5 Saudi Arabia: Biopharmaceuticals Market, by Recombinant Proteins, 2019–2028 (US$ Million)
9.4.5.2.1.6 Saudi Arabia: Biopharmaceuticals Market, by Recombinant Hormones, 2019–2028 (US$ Million)
9.4.5.2.1.7 Saudi Arabia: Biopharmaceuticals Market, by Recombinant Enzymes, 2019–2028 (US$ Million)
9.4.5.2.1.8 Saudi Arabia: Biopharmaceuticals Market, by Cell & Gene Therapies, 2019–2028 (US$ Million)
9.4.5.2.2 Saudi Arabia: Biopharmaceuticals Market, by Application, 2019–2028 (US$ Million)
9.4.5.3 South Africa: Biopharmaceuticals Market – Revenue and Forecast to 2028 (US$ Million)
9.4.5.3.1 South Africa: Biopharmaceuticals Market, by Product Type, 2019–2028 (US$ Million)
9.4.5.3.1.1 South Africa: Biopharmaceuticals Market, by Recombinant Vaccines, 2019–2028 (US$ Million)
9.4.5.3.1.2 South Africa: Biopharmaceuticals Market, by Conventional Vaccines, 2019–2028 (US$ Million)
9.4.5.3.1.3 South Africa: Biopharmaceuticals Market, by Recombinant Growth Factors, 2019–2028 (US$ Million)
9.4.5.3.1.4 South Africa: Biopharmaceuticals Market, by Purified Proteins, 2019–2028 (US$ Million)
9.4.5.3.1.5 South Africa: Biopharmaceuticals Market, by Recombinant Proteins, 2019–2028 (US$ Million)
9.4.5.3.1.6 South Africa: Biopharmaceuticals Market, by Recombinant Hormones, 2019–2028 (US$ Million)
9.4.5.3.1.7 South Africa: Biopharmaceuticals Market, by Recombinant Enzymes, 2019–2028 (US$ Million)
9.4.5.3.1.8 South Africa: Biopharmaceuticals Market, by Cell & Gene Therapies, 2019–2028 (US$ Million)
9.4.5.3.2 South Africa: Biopharmaceuticals Market, by Application, 2019–2028 (US$ Million)
9.4.5.4 Rest of Middle East & Africa: Biopharmaceuticals Market – Revenue and Forecast to 2028 (US$ Million)
9.4.5.4.1 Rest of Middle East & Africa: Biopharmaceuticals Market, by Product Type, 2019–2028 (US$ Million)
9.4.5.4.1.1 Rest of Middle East & Africa: Biopharmaceuticals Market, by Recombinant Vaccines, 2019–2028 (US$ Million)
9.4.5.4.1.2 Rest of Middle East & Africa: Biopharmaceuticals Market, by Conventional Vaccines, 2019–2028 (US$ Million)
9.4.5.4.1.3 Rest of Middle East & Africa: Biopharmaceuticals Market, by Recombinant Growth Factors, 2019–2028 (US$ Million)
9.4.5.4.1.4 Rest of Middle East & Africa: Biopharmaceuticals Market, by Purified Proteins, 2019–2028 (US$ Million)
9.4.5.4.1.5 Rest of Middle East & Africa: Biopharmaceuticals Market, by Recombinant Proteins, 2019–2028 (US$ Million)
9.4.5.4.1.6 Rest of Middle East & Africa: Biopharmaceuticals Market, by Recombinant Hormones, 2019–2028 (US$ Million)
9.4.5.4.1.7 Rest of Middle East & Africa: Biopharmaceuticals Market, by Recombinant Enzymes, 2019–2028 (US$ Million)
9.4.5.4.1.8 Rest of Middle East & Africa: Biopharmaceuticals Market, by Cell & Gene Therapies, 2019–2028 (US$ Million)
9.4.5.4.2 Rest of Middle East & Africa: Biopharmaceuticals Market, by Application, 2019–2028 (US$ Million)
9.5 South & Central America Biopharmaceuticals Market
9.5.1 Overview
9.5.2 South & Central America: Biopharmaceuticals Market – Revenue and Forecast to 2028 (US$ Million)
9.5.3 South & Central America: Biopharmaceuticals Market, by Product Type, 2019–2028 (US$ Million)
9.5.3.1 South & Central America: Biopharmaceuticals Market, by Recombinant Vaccines, 2019–2028 (US$ Million)
9.5.3.2 South & Central America: Biopharmaceuticals Market, by Conventional Vaccines, 2019–2028 (US$ Million)
9.5.3.3 South & Central America: Biopharmaceuticals Market, by Recombinant Growth Factors, 2019–2028 (US$ Million)
9.5.3.4 South & Central America: Biopharmaceuticals Market, by Purified Proteins, 2019–2028 (US$ Million)
9.5.3.5 South & Central America: Biopharmaceuticals Market, by Recombinant Proteins, 2019–2028 (US$ Million)
9.5.3.6 South & Central America: Biopharmaceuticals Market, by Recombinant Hormones, 2019–2028 (US$ Million)
9.5.3.7 South & Central America: Biopharmaceuticals Market, by Recombinant Enzymes, 2019–2028 (US$ Million)
9.5.3.8 South & Central America: Biopharmaceuticals Market, by Cell & Gene Therapies, 2019–2028 (US$ Million)
9.5.4 South & Central America: Biopharmaceuticals Market, by Application, 2019–2028 (US$ Million)
9.5.5 South & Central America: Biopharmaceuticals Market, by Country, 2021 & 2028 (%)
9.5.5.1 Brazil: Biopharmaceuticals Market – Revenue and Forecast to 2028 (US$ Million)
9.5.5.1.1 Brazil: Biopharmaceuticals Market, by Product Type, 2019–2028 (US$ Million)
9.5.5.1.1.1 Brazil: Biopharmaceuticals Market, by Recombinant Vaccines, 2019–2028 (US$ Million)
9.5.5.1.1.2 Brazil: Biopharmaceuticals Market, by Conventional Vaccines, 2019–2028 (US$ Million)
9.5.5.1.1.3 Brazil: Biopharmaceuticals Market, by Recombinant Growth Factors, 2019–2028 (US$ Million)
9.5.5.1.1.4 Brazil: Biopharmaceuticals Market, by Purified Proteins, 2019–2028 (US$ Million)
9.5.5.1.1.5 Brazil: Biopharmaceuticals Market, by Recombinant Proteins, 2019–2028 (US$ Million)
9.5.5.1.1.6 Brazil: Biopharmaceuticals Market, by Recombinant Hormones, 2019–2028 (US$ Million)
9.5.5.1.1.7 Brazil: Biopharmaceuticals Market, by Recombinant Enzymes, 2019–2028 (US$ Million)
9.5.5.1.1.8 Brazil: Biopharmaceuticals Market, by Cell & Gene Therapies, 2019–2028 (US$ Million)
9.5.5.1.2 Brazil: Biopharmaceuticals Market, by Application, 2019–2028 (US$ Million)
9.5.5.2 Argentina: Biopharmaceuticals Market – Revenue and Forecast to 2028 (US$ Million)
9.5.5.2.1 Argentina: Biopharmaceuticals Market, by Product Type, 2019–2028 (US$ Million)
9.5.5.2.1.1 Argentina: Biopharmaceuticals Market, by Recombinant Vaccines, 2019–2028 (US$ Million)
9.5.5.2.1.2 Argentina: Biopharmaceuticals Market, by Conventional Vaccines, 2019–2028 (US$ Million)
9.5.5.2.1.3 Argentina: Biopharmaceuticals Market, by Recombinant Growth Factors, 2019–2028 (US$ Million)
9.5.5.2.1.4 Argentina: Biopharmaceuticals Market, by Purified Proteins, 2019–2028 (US$ Million)
9.5.5.2.1.5 Argentina: Biopharmaceuticals Market, by Recombinant Proteins, 2019–2028 (US$ Million)
9.5.5.2.1.6 Argentina: Biopharmaceuticals Market, by Recombinant Hormones, 2019–2028 (US$ Million)
9.5.5.2.1.7 Argentina: Biopharmaceuticals Market, by Recombinant Enzymes, 2019–2028 (US$ Million)
9.5.5.2.1.8 Argentina: Biopharmaceuticals Market, by Cell & Gene Therapies, 2019–2028 (US$ Million)
9.5.5.2.2 Argentina: Biopharmaceuticals Market, by Application, 2019–2028 (US$ Million)
9.5.5.3 Rest of South & Central America: Biopharmaceuticals Market – Revenue and Forecast to 2028 (US$ Million)
9.5.5.3.1 Rest of South & Central America: Biopharmaceuticals Market, by Product Type, 2019–2028 (US$ Million)
9.5.5.3.1.1 Rest of South & Central America: Biopharmaceuticals Market, by Recombinant Vaccines, 2019–2028 (US$ Million)
9.5.5.3.1.2 Rest of South & Central America: Biopharmaceuticals Market, by Conventional Vaccines, 2019–2028 (US$ Million)
9.5.5.3.1.3 Rest of South & Central America: Biopharmaceuticals Market, by Recombinant Growth Factors, 2019–2028 (US$ Million)
9.5.5.3.1.4 Rest of South & Central America: Biopharmaceuticals Market, by Purified Proteins, 2019–2028 (US$ Million)
9.5.5.3.1.5 Rest of South & Central America: Biopharmaceuticals Market, by Recombinant Proteins, 2019–2028 (US$ Million)
9.5.5.3.1.6 Rest of South & Central America: Biopharmaceuticals Market, by Recombinant Hormones, 2019–2028 (US$ Million)
9.5.5.3.1.7 Rest of South & Central America: Biopharmaceuticals Market, by Recombinant Enzymes, 2019–2028 (US$ Million)
9.5.5.3.1.8 Rest of South & Central America: Biopharmaceuticals Market, by Cell & Gene Therapies, 2019–2028 (US$ Million)
9.5.5.3.2 Rest of South & Central America: Biopharmaceuticals Market, by Application, 2019–2028 (US$ Million)
10. Impact of COVID-19 Pandemic on Biopharmaceutical Market
10.1 North America: Impact Assessment of COVID-19 Pandemic
10.2 Europe: Impact Assessment of COVID-19 Pandemic
10.3 Asia Pacific: Impact Assessment of COVID-19 Pandemic
10.4 Middle East & Africa: Impact Assessment of COVID-19 Pandemic
10.5 South & Central America: Impact Assessment of COVID-19 Pandemic
11. Biopharmaceuticals Market – Industry Landscape
11.1 Overview
11.2 Growth Strategies in Biopharmaceuticals Market
11.3 Organic Growth Strategies
11.3.1 Overview
11.4 Inorganic Growth Strategies
11.4.1 Overview
12. Company Profiles
12.1 Amgen Inc
12.1.1 Key Facts
12.1.2 Business Description
12.1.3 Products and Services
12.1.4 Financial Overview
12.1.5 SWOT Analysis
12.1.6 Key Developments
12.2 AbbVie Inc
12.2.1 Key Facts
12.2.2 Business Description
12.2.3 Products and Services
12.2.4 Financial Overview
12.2.5 SWOT Analysis
12.2.6 Key Developments
12.3 Eli Lilly and Co
12.3.1 Key Facts
12.3.2 Business Description
12.3.3 Products and Services
12.3.4 Financial Overview
12.3.5 SWOT Analysis
12.3.6 Key Developments
12.4 Bristol-Myers Squibb Co
12.4.1 Key Facts
12.4.2 Business Description
12.4.3 Products and Services
12.4.4 Financial Overview
12.4.5 SWOT Analysis
12.4.6 Key Developments
12.5 Johnson & Johnson
12.5.1 Key Facts
12.5.2 Business Description
12.5.3 Products and Services
12.5.4 Financial Overview
12.5.5 SWOT Analysis
12.5.6 Key Developments
12.6 Boehringer Ingelheim International GmbH
12.6.1 Key Facts
12.6.2 Business Description
12.6.3 Products and Services
12.6.4 Financial Overview
12.6.5 SWOT Analysis
12.6.6 Key Developments
12.7 Thermo Fisher Scientific Inc
12.7.1 Key Facts
12.7.2 Business Description
12.7.3 Products and Services
12.7.4 Financial Overview
12.7.5 SWOT Analysis
12.7.6 Key Developments
12.8 AGC Biologics AS
12.8.1 Key Facts
12.8.2 Business Description
12.8.3 Products and Services
12.8.4 Financial Overview
12.8.5 SWOT Analysis
12.8.6 Key Developments
12.9 Lonza Group AG
12.9.1 Key Facts
12.9.2 Business Description
12.9.3 Products and Services
12.9.4 Financial Overview
12.9.5 SWOT Analysis
12.9.6 Key Developments
12.10 WuXi Biologics Inc
12.10.1 Key Facts
12.10.2 Business Description
12.10.3 Products and Services
12.10.4 Financial Overview
12.10.5 SWOT Analysis
12.10.6 Key Developments
13. Appendix
13.1 About The Insight Partners
13.2 Glossary of Terms
LIST OF TABLES
Table 1. North America Biopharmaceuticals Market, by Product Type – Revenue and Forecast to 2028 (US$ Million)
Table 2. North America Biopharmaceuticals Market, by Recombinant Vaccines – Revenue and Forecast to 2028 (US$ Million)
Table 3. North America Biopharmaceuticals Market, by Conventional Vaccines – Revenue and Forecast to 2028 (US$ Million)
Table 4. North America Biopharmaceuticals Market, by Recombinant Growth Factors – Revenue and Forecast to 2028 (US$ Million)
Table 5. North America Biopharmaceuticals Market, by Purified Proteins – Revenue and Forecast to 2028 (US$ Million)
Table 6. North America Biopharmaceuticals Market, by Recombinant Proteins – Revenue and Forecast to 2028 (US$ Million)
Table 7. North America Biopharmaceuticals Market, by Recombinant Hormones – Revenue and Forecast to 2028 (US$ Million)
Table 8. North America Biopharmaceuticals Market, by Recombinant Enzymes – Revenue and Forecast to 2028 (US$ Million)
Table 9. North America Biopharmaceuticals Market, by Cell & Gene Therapies – Revenue and Forecast to 2028 (US$ Million)
Table 10. North America Biopharmaceuticals Market, by Application – Revenue and Forecast to 2028 (US$ Million)
Table 11. United States Biopharmaceuticals Market, by Product Type – Revenue and Forecast to 2028 (US$ Million)
Table 12. United States Biopharmaceuticals Market, by Recombinant Vaccines – Revenue and Forecast to 2028 (US$ Million)
Table 13. United States Biopharmaceuticals Market, by Conventional Vaccines – Revenue and Forecast to 2028 (US$ Million)
Table 14. United States Biopharmaceuticals Market, by Recombinant Growth Factors – Revenue and Forecast to 2028 (US$ Million)
Table 15. United States Biopharmaceuticals Market, by Purified Proteins – Revenue and Forecast to 2028 (US$ Million)
Table 16. United States Biopharmaceuticals Market, by Recombinant Proteins – Revenue and Forecast to 2028 (US$ Million)
Table 17. United States Biopharmaceuticals Market, by Recombinant Hormones – Revenue and Forecast to 2028 (US$ Million)
Table 18. United States Biopharmaceuticals Market, by Recombinant Enzymes – Revenue and Forecast to 2028 (US$ Million)
Table 19. United States Biopharmaceuticals Market, by Cell & Gene Therapies – Revenue and Forecast to 2028 (US$ Million)
Table 20. United States Biopharmaceuticals Market, by Application – Revenue and Forecast to 2028 (US$ Million)
Table 21. Canada Biopharmaceuticals Market, by Product Type – Revenue and Forecast to 2028 (US$ Million)
Table 22. Canada Biopharmaceuticals Market, by Recombinant Vaccines – Revenue and Forecast to 2028 (US$ Million)
Table 23. Canada Biopharmaceuticals Market, by Conventional Vaccines – Revenue and Forecast to 2028 (US$ Million)
Table 24. Canada Biopharmaceuticals Market, by Recombinant Growth Factors – Revenue and Forecast to 2028 (US$ Million)
Table 25. Canada Biopharmaceuticals Market, by Purified Proteins – Revenue and Forecast to 2028 (US$ Million)
Table 26. Canada Biopharmaceuticals Market, by Recombinant Proteins – Revenue and Forecast to 2028 (US$ Million)
Table 27. Canada Biopharmaceuticals Market, by Recombinant Hormones – Revenue and Forecast to 2028 (US$ Million)
Table 28. Canada Biopharmaceuticals Market, by Recombinant Enzymes – Revenue and Forecast to 2028 (US$ Million)
Table 29. Canada Biopharmaceuticals Market, by Cell & Gene Therapies – Revenue and Forecast to 2028 (US$ Million)
Table 30. Canada Biopharmaceuticals Market, by Application – Revenue and Forecast to 2028 (US$ Million)
Table 31. Mexico Biopharmaceuticals Market, by Product Type – Revenue and Forecast to 2028 (US$ Million)
Table 32. Mexico Biopharmaceuticals Market, by Recombinant Vaccines – Revenue and Forecast to 2028 (US$ Million)
Table 33. Mexico Biopharmaceuticals Market, by Conventional Vaccines – Revenue and Forecast to 2028 (US$ Million)
Table 34. Mexico Biopharmaceuticals Market, by Recombinant Growth Factors – Revenue and Forecast to 2028 (US$ Million)
Table 35. Mexico Biopharmaceuticals Market, by Purified Proteins – Revenue and Forecast to 2028 (US$ Million)
Table 36. Mexico Biopharmaceuticals Market, by Recombinant Proteins – Revenue and Forecast to 2028 (US$ Million)
Table 37. Mexico Biopharmaceuticals Market, by Recombinant Hormones – Revenue and Forecast to 2028 (US$ Million)
Table 38. Mexico Biopharmaceuticals Market, by Recombinant Enzymes – Revenue and Forecast to 2028 (US$ Million)
Table 39. Mexico Biopharmaceuticals Market, by Cell & Gene Therapies – Revenue and Forecast to 2028 (US$ Million)
Table 40. Mexico Biopharmaceuticals Market, by Application – Revenue and Forecast to 2028 (US$ Million)
Table 41. Europe Biopharmaceuticals Market, by Product Type – Revenue and Forecast to 2028 (US$ Million)
Table 42. Europe Biopharmaceuticals Market, by Recombinant Vaccines – Revenue and Forecast to 2028 (US$ Million)
Table 43. Europe Biopharmaceuticals Market, by Conventional Vaccines – Revenue and Forecast to 2028 (US$ Million)
Table 44. Europe Biopharmaceuticals Market, by Recombinant Growth Factors – Revenue and Forecast to 2028 (US$ Million)
Table 45. Europe Biopharmaceuticals Market, by Purified Proteins – Revenue and Forecast to 2028 (US$ Million)
Table 46. Europe Biopharmaceuticals Market, by Recombinant Proteins – Revenue and Forecast to 2028 (US$ Million)
Table 47. Europe Biopharmaceuticals Market, by Recombinant Hormones – Revenue and Forecast to 2028 (US$ Million)
Table 48. Europe Biopharmaceuticals Market, by Recombinant Enzymes – Revenue and Forecast to 2028 (US$ Million)
Table 49. Europe Biopharmaceuticals Market, by Cell & Gene Therapies – Revenue and Forecast to 2028 (US$ Million)
Table 50. Europe Biopharmaceuticals Market, by Application – Revenue and Forecast to 2028 (US$ Million)
Table 51. United Kingdom Biopharmaceuticals Market, by Product Type – Revenue and Forecast to 2028 (US$ Million)
Table 52. United Kingdom Biopharmaceuticals Market, by Recombinant Vaccines – Revenue and Forecast to 2028 (US$ Million)
Table 53. United Kingdom Biopharmaceuticals Market, by Conventional Vaccines – Revenue and Forecast to 2028 (US$ Million)
Table 54. United Kingdom Biopharmaceuticals Market, by Recombinant Growth Factors – Revenue and Forecast to 2028 (US$ Million)
Table 55. United Kingdom Biopharmaceuticals Market, by Purified Proteins – Revenue and Forecast to 2028 (US$ Million)
Table 56. United Kingdom Biopharmaceuticals Market, by Recombinant Proteins – Revenue and Forecast to 2028 (US$ Million)
Table 57. United Kingdom Biopharmaceuticals Market, by Recombinant Hormones – Revenue and Forecast to 2028 (US$ Million)
Table 58. United Kingdom Biopharmaceuticals Market, by Recombinant Enzymes – Revenue and Forecast to 2028 (US$ Million)
Table 59. United Kingdom Biopharmaceuticals Market, by Cell & Gene Therapies – Revenue and Forecast to 2028 (US$ Million)
Table 60. United Kingdom Biopharmaceuticals Market, by Application – Revenue and Forecast to 2028 (US$ Million)
Table 61. Germany Biopharmaceuticals Market, by Product Type – Revenue and Forecast to 2028 (US$ Million)
Table 62. Germany Biopharmaceuticals Market, by Recombinant Vaccines – Revenue and Forecast to 2028 (US$ Million)
Table 63. Germany Biopharmaceuticals Market, by Conventional Vaccines – Revenue and Forecast to 2028 (US$ Million)
Table 64. Germany Biopharmaceuticals Market, by Recombinant Growth Factors – Revenue and Forecast to 2028 (US$ Million)
Table 65. Germany Biopharmaceuticals Market, by Purified Proteins – Revenue and Forecast to 2028 (US$ Million)
Table 66. Germany Biopharmaceuticals Market, by Recombinant Proteins – Revenue and Forecast to 2028 (US$ Million)
Table 67. Germany Biopharmaceuticals Market, by Recombinant Hormones – Revenue and Forecast to 2028 (US$ Million)
Table 68. Germany Biopharmaceuticals Market, by Recombinant Enzymes – Revenue and Forecast to 2028 (US$ Million)
Table 69. Germany Biopharmaceuticals Market, by Cell & Gene Therapies – Revenue and Forecast to 2028 (US$ Million)
Table 70. Germany Biopharmaceuticals Market, by Application – Revenue and Forecast to 2028 (US$ Million)
Table 71. France Biopharmaceuticals Market, by Product Type – Revenue and Forecast to 2028 (US$ Million)
Table 72. France Biopharmaceuticals Market, by Recombinant Vaccines – Revenue and Forecast to 2028 (US$ Million)
Table 73. France Biopharmaceuticals Market, by Conventional Vaccines – Revenue and Forecast to 2028 (US$ Million)
Table 74. France Biopharmaceuticals Market, by Recombinant Growth Factors – Revenue and Forecast to 2028 (US$ Million)
Table 75. France Biopharmaceuticals Market, by Purified Proteins – Revenue and Forecast to 2028 (US$ Million)
Table 76. France Biopharmaceuticals Market, by Recombinant Proteins – Revenue and Forecast to 2028 (US$ Million)
Table 77. France Biopharmaceuticals Market, by Recombinant Hormones – Revenue and Forecast to 2028 (US$ Million)
Table 78. France Biopharmaceuticals Market, by Recombinant Enzymes – Revenue and Forecast to 2028 (US$ Million)
Table 79. France Biopharmaceuticals Market, by Cell & Gene Therapies – Revenue and Forecast to 2028 (US$ Million)
Table 80. France Biopharmaceuticals Market, by Application – Revenue and Forecast to 2028 (US$ Million)
Table 81. Italy Biopharmaceuticals Market, by Product Type – Revenue and Forecast to 2028 (US$ Million)
Table 82. Italy Biopharmaceuticals Market, by Recombinant Vaccines – Revenue and Forecast to 2028 (US$ Million)
Table 83. Italy Biopharmaceuticals Market, by Conventional Vaccines – Revenue and Forecast to 2028 (US$ Million)
Table 84. Italy Biopharmaceuticals Market, by Recombinant Growth Factors – Revenue and Forecast to 2028 (US$ Million)
Table 85. Italy Biopharmaceuticals Market, by Purified Proteins – Revenue and Forecast to 2028 (US$ Million)
Table 86. Italy Biopharmaceuticals Market, by Recombinant Proteins – Revenue and Forecast to 2028 (US$ Million)
Table 87. Italy Biopharmaceuticals Market, by Recombinant Hormones – Revenue and Forecast to 2028 (US$ Million)
Table 88. Italy Biopharmaceuticals Market, by Recombinant Enzymes – Revenue and Forecast to 2028 (US$ Million)
Table 89. Italy Biopharmaceuticals Market, by Cell & Gene Therapies – Revenue and Forecast to 2028 (US$ Million)
Table 90. Italy Biopharmaceuticals Market, by Application – Revenue and Forecast to 2028 (US$ Million)
Table 91. Spain Biopharmaceuticals Market, by Product Type – Revenue and Forecast to 2028 (US$ Million)
Table 92. Spain Biopharmaceuticals Market, by Recombinant Vaccines – Revenue and Forecast to 2028 (US$ Million)
Table 93. Spain Biopharmaceuticals Market, by Conventional Vaccines – Revenue and Forecast to 2028 (US$ Million)
Table 94. Spain Biopharmaceuticals Market, by Recombinant Growth Factors – Revenue and Forecast to 2028 (US$ Million)
Table 95. Spain Biopharmaceuticals Market, by Purified Proteins – Revenue and Forecast to 2028 (US$ Million)
Table 96. Spain Biopharmaceuticals Market, by Recombinant Proteins – Revenue and Forecast to 2028 (US$ Million)
Table 97. Spain Biopharmaceuticals Market, by Recombinant Hormones – Revenue and Forecast to 2028 (US$ Million)
Table 98. Spain Biopharmaceuticals Market, by Recombinant Enzymes – Revenue and Forecast to 2028 (US$ Million)
Table 99. Spain Biopharmaceuticals Market, by Cell & Gene Therapies – Revenue and Forecast to 2028 (US$ Million)
Table 100. Spain Biopharmaceuticals Market, by Application – Revenue and Forecast to 2028 (US$ Million)
Table 101. Rest of Europe Biopharmaceuticals Market, by Product Type – Revenue and Forecast to 2028 (US$ Million)
Table 102. Rest of Europe Biopharmaceuticals Market, by Recombinant Vaccines – Revenue and Forecast to 2028 (US$ Million)
Table 103. Rest of Europe Biopharmaceuticals Market, by Conventional Vaccines – Revenue and Forecast to 2028 (US$ Million)
Table 104. Rest of Europe Biopharmaceuticals Market, by Recombinant Growth Factors – Revenue and Forecast to 2028 (US$ Million)
Table 105. Rest of Europe Biopharmaceuticals Market, by Purified Proteins – Revenue and Forecast to 2028 (US$ Million)
Table 106. Rest of Europe Biopharmaceuticals Market, by Recombinant Proteins – Revenue and Forecast to 2028 (US$ Million)
Table 107. Rest of Europe Biopharmaceuticals Market, by Recombinant Hormones – Revenue and Forecast to 2028 (US$ Million)
Table 108. Rest of Europe Biopharmaceuticals Market, by Recombinant Enzymes – Revenue and Forecast to 2028 (US$ Million)
Table 109. Rest of Europe Biopharmaceuticals Market, by Cell & Gene Therapies – Revenue and Forecast to 2028 (US$ Million)
Table 110. Rest of Europe Biopharmaceuticals Market, by Application – Revenue and Forecast to 2028 (US$ Million)
Table 111. Asia Pacific Biopharmaceuticals Market, by Product Type – Revenue and Forecast to 2028 (US$ Million)
Table 112. Asia Pacific Biopharmaceuticals Market, by Recombinant Vaccines – Revenue and Forecast to 2028 (US$ Million)
Table 113. Asia Pacific Biopharmaceuticals Market, by Conventional Vaccines – Revenue and Forecast to 2028 (US$ Million)
Table 114. Asia Pacific Biopharmaceuticals Market, by Recombinant Growth Factors – Revenue and Forecast to 2028 (US$ Million)
Table 115. Asia Pacific Biopharmaceuticals Market, by Purified Proteins – Revenue and Forecast to 2028 (US$ Million)
Table 116. Asia Pacific Biopharmaceuticals Market, by Recombinant Proteins – Revenue and Forecast to 2028 (US$ Million)
Table 117. Asia Pacific Biopharmaceuticals Market, by Recombinant Hormones – Revenue and Forecast to 2028 (US$ Million)
Table 118. Asia Pacific Biopharmaceuticals Market, by Recombinant Enzymes – Revenue and Forecast to 2028 (US$ Million)
Table 119. Asia Pacific Biopharmaceuticals Market, by Cell & Gene Therapies – Revenue and Forecast to 2028 (US$ Million)
Table 120. Asia Pacific Biopharmaceuticals Market, by Application – Revenue and Forecast to 2028 (US$ Million)
Table 121. China Biopharmaceuticals Market, by Product Type – Revenue and Forecast to 2028 (US$ Million)
Table 122. China Biopharmaceuticals Market, by Recombinant Vaccines – Revenue and Forecast to 2028 (US$ Million)
Table 123. China Biopharmaceuticals Market, by Conventional Vaccines – Revenue and Forecast to 2028 (US$ Million)
Table 124. China Biopharmaceuticals Market, by Recombinant Growth Factors – Revenue and Forecast to 2028 (US$ Million)
Table 125. China Biopharmaceuticals Market, by Purified Proteins – Revenue and Forecast to 2028 (US$ Million)
Table 126. China Biopharmaceuticals Market, by Recombinant Proteins – Revenue and Forecast to 2028 (US$ Million)
Table 127. China Biopharmaceuticals Market, by Recombinant Hormones – Revenue and Forecast to 2028 (US$ Million)
Table 128. China Biopharmaceuticals Market, by Recombinant Enzymes – Revenue and Forecast to 2028 (US$ Million)
Table 129. China Biopharmaceuticals Market, by Cell & Gene Therapies – Revenue and Forecast to 2028 (US$ Million)
Table 130. China Biopharmaceuticals Market, by Application – Revenue and Forecast to 2028 (US$ Million)
Table 131. Japan Biopharmaceuticals Market, by Product Type – Revenue and Forecast to 2028 (US$ Million)
Table 132. Japan Biopharmaceuticals Market, by Recombinant Vaccines – Revenue and Forecast to 2028 (US$ Million)
Table 133. Japan Biopharmaceuticals Market, by Conventional Vaccines – Revenue and Forecast to 2028 (US$ Million)
Table 134. Japan Biopharmaceuticals Market, by Recombinant Growth Factors – Revenue and Forecast to 2028 (US$ Million)
Table 135. Japan Biopharmaceuticals Market, by Purified Proteins – Revenue and Forecast to 2028 (US$ Million)
Table 136. Japan Biopharmaceuticals Market, by Recombinant Proteins – Revenue and Forecast to 2028 (US$ Million)
Table 137. Japan Biopharmaceuticals Market, by Recombinant Hormones – Revenue and Forecast to 2028 (US$ Million)
Table 138. Japan Biopharmaceuticals Market, by Recombinant Enzymes – Revenue and Forecast to 2028 (US$ Million)
Table 139. Japan Biopharmaceuticals Market, by Cell & Gene Therapies – Revenue and Forecast to 2028 (US$ Million)
Table 140. Japan Biopharmaceuticals Market, by Application – Revenue and Forecast to 2028 (US$ Million)
Table 141. India Biopharmaceuticals Market, by Product Type – Revenue and Forecast to 2028 (US$ Million)
Table 142. India Biopharmaceuticals Market, by Recombinant Vaccines – Revenue and Forecast to 2028 (US$ Million)
Table 143. India Biopharmaceuticals Market, by Conventional Vaccines – Revenue and Forecast to 2028 (US$ Million)
Table 144. India Biopharmaceuticals Market, by Recombinant Growth Factors – Revenue and Forecast to 2028 (US$ Million)
Table 145. India Biopharmaceuticals Market, by Purified Proteins – Revenue and Forecast to 2028 (US$ Million)
Table 146. India Biopharmaceuticals Market, by Recombinant Proteins – Revenue and Forecast to 2028 (US$ Million)
Table 147. India Biopharmaceuticals Market, by Recombinant Hormones – Revenue and Forecast to 2028 (US$ Million)
Table 148. India Biopharmaceuticals Market, by Recombinant Enzymes – Revenue and Forecast to 2028 (US$ Million)
Table 149. India Biopharmaceuticals Market, by Cell & Gene Therapies – Revenue and Forecast to 2028 (US$ Million)
Table 150. India Biopharmaceuticals Market, by Application – Revenue and Forecast to 2028 (US$ Million)
Table 151. South Korea Biopharmaceuticals Market, by Product Type – Revenue and Forecast to 2028 (US$ Million)
Table 152. South Korea Biopharmaceuticals Market, by Recombinant Vaccines – Revenue and Forecast to 2028 (US$ Million)
Table 153. South Korea Biopharmaceuticals Market, by Conventional Vaccines – Revenue and Forecast to 2028 (US$ Million)
Table 154. South Korea Biopharmaceuticals Market, by Recombinant Growth Factors – Revenue and Forecast to 2028 (US$ Million)
Table 155. South Korea Biopharmaceuticals Market, by Purified Proteins – Revenue and Forecast to 2028 (US$ Million)
Table 156. South Korea Biopharmaceuticals Market, by Recombinant Proteins – Revenue and Forecast to 2028 (US$ Million)
Table 157. South Korea Biopharmaceuticals Market, by Recombinant Hormones – Revenue and Forecast to 2028 (US$ Million)
Table 158. South Korea Biopharmaceuticals Market, by Recombinant Enzymes – Revenue and Forecast to 2028 (US$ Million)
Table 159. South Korea Biopharmaceuticals Market, by Cell & Gene Therapies – Revenue and Forecast to 2028 (US$ Million)
Table 160. South Korea Biopharmaceuticals Market, by Application – Revenue and Forecast to 2028 (US$ Million)
Table 161. Australia Biopharmaceuticals Market, by Product Type – Revenue and Forecast to 2028 (US$ Million)
Table 162. Australia Biopharmaceuticals Market, by Recombinant Vaccines – Revenue and Forecast to 2028 (US$ Million)
Table 163. Australia Biopharmaceuticals Market, by Conventional Vaccines – Revenue and Forecast to 2028 (US$ Million)
Table 164. Australia Biopharmaceuticals Market, by Recombinant Growth Factors – Revenue and Forecast to 2028 (US$ Million)
Table 165. Australia Biopharmaceuticals Market, by Purified Proteins – Revenue and Forecast to 2028 (US$ Million)
Table 166. Australia Biopharmaceuticals Market, by Recombinant Proteins – Revenue and Forecast to 2028 (US$ Million)
Table 167. Australia Biopharmaceuticals Market, by Recombinant Hormones – Revenue and Forecast to 2028 (US$ Million)
Table 168. Australia Biopharmaceuticals Market, by Recombinant Enzymes – Revenue and Forecast to 2028 (US$ Million)
Table 169. Australia Biopharmaceuticals Market, by Cell & Gene Therapies – Revenue and Forecast to 2028 (US$ Million)
Table 170. Australia Biopharmaceuticals Market, by Application – Revenue and Forecast to 2028 (US$ Million)
Table 171. Rest of Asia Pacific Biopharmaceuticals Market, by Product Type – Revenue and Forecast to 2028 (US$ Million)
Table 172. Rest of Asia Pacific Biopharmaceuticals Market, by Recombinant Vaccines – Revenue and Forecast to 2028 (US$ Million)
Table 173. Rest of Asia Pacific Biopharmaceuticals Market, by Conventional Vaccines – Revenue and Forecast to 2028 (US$ Million)
Table 174. Rest of Asia Pacific Biopharmaceuticals Market, by Recombinant Growth Factors – Revenue and Forecast to 2028 (US$ Million)
Table 175. Rest of Asia Pacific Biopharmaceuticals Market, by Purified Proteins – Revenue and Forecast to 2028 (US$ Million)
Table 176. Rest of Asia Pacific Biopharmaceuticals Market, by Recombinant Proteins – Revenue and Forecast to 2028 (US$ Million)
Table 177. Rest of Asia Pacific Biopharmaceuticals Market, by Recombinant Hormones – Revenue and Forecast to 2028 (US$ Million)
Table 178. Rest of Asia Pacific Biopharmaceuticals Market, by Recombinant Enzymes – Revenue and Forecast to 2028 (US$ Million)
Table 179. Rest of Asia Pacific Biopharmaceuticals Market, by Cell & Gene Therapies – Revenue and Forecast to 2028 (US$ Million)
Table 180. Rest of Asia Pacific Biopharmaceuticals Market, by Application – Revenue and Forecast to 2028 (US$ Million)
Table 181. Middle East & Africa Biopharmaceuticals Market, by Product Type – Revenue and Forecast to 2028 (US$ Million)
Table 182. Middle East & Africa Biopharmaceuticals Market, by Recombinant Vaccines – Revenue and Forecast to 2028 (US$ Million)
Table 183. Middle East & Africa Biopharmaceuticals Market, by Conventional Vaccines – Revenue and Forecast to 2028 (US$ Million)
Table 184. Middle East & Africa Biopharmaceuticals Market, by Recombinant Growth Factors – Revenue and Forecast to 2028 (US$ Million)
Table 185. Middle East & Africa Biopharmaceuticals Market, by Purified Proteins – Revenue and Forecast to 2028 (US$ Million)
Table 186. Middle East & Africa Biopharmaceuticals Market, by Recombinant Proteins – Revenue and Forecast to 2028 (US$ Million)
Table 187. Middle East & Africa Biopharmaceuticals Market, by Recombinant Hormones – Revenue and Forecast to 2028 (US$ Million)
Table 188. Middle East & Africa Biopharmaceuticals Market, by Recombinant Enzymes – Revenue and Forecast to 2028 (US$ Million)
Table 189. Middle East & Africa Biopharmaceuticals Market, by Cell & Gene Therapies – Revenue and Forecast to 2028 (US$ Million)
Table 190. Middle East & Africa Biopharmaceuticals Market, by Application – Revenue and Forecast to 2028 (US$ Million)
Table 191. UAE Biopharmaceuticals Market, by Product Type – Revenue and Forecast to 2028 (US$ Million)
Table 192. UAE Biopharmaceuticals Market, by Recombinant Vaccines – Revenue and Forecast to 2028 (US$ Million)
Table 193. UAE Biopharmaceuticals Market, by Conventional Vaccines – Revenue and Forecast to 2028 (US$ Million)
Table 194. UAE Biopharmaceuticals Market, by Recombinant Growth Factors – Revenue and Forecast to 2028 (US$ Million)
Table 195. UAE Biopharmaceuticals Market, by Purified Proteins – Revenue and Forecast to 2028 (US$ Million)
Table 196. UAE Biopharmaceuticals Market, by Recombinant Proteins – Revenue and Forecast to 2028 (US$ Million)
Table 197. UAE Biopharmaceuticals Market, by Recombinant Hormones – Revenue and Forecast to 2028 (US$ Million)
Table 198. UAE Biopharmaceuticals Market, by Recombinant Enzymes – Revenue and Forecast to 2028 (US$ Million)
Table 199. UAE Biopharmaceuticals Market, by Cell & Gene Therapies – Revenue and Forecast to 2028 (US$ Million)
Table 200. UAE Biopharmaceuticals Market, by Application – Revenue and Forecast to 2028 (US$ Million)
Table 201. Saudi Arabia Biopharmaceuticals Market, by Product Type – Revenue and Forecast to 2028 (US$ Million)
Table 202. Saudi Arabia Biopharmaceuticals Market, by Recombinant Vaccines – Revenue and Forecast to 2028 (US$ Million)
Table 203. Saudi Arabia Biopharmaceuticals Market, by Conventional Vaccines – Revenue and Forecast to 2028 (US$ Million)
Table 204. Saudi Arabia Biopharmaceuticals Market, by Recombinant Growth Factors – Revenue and Forecast to 2028 (US$ Million)
Table 205. Saudi Arabia Biopharmaceuticals Market, by Purified Proteins – Revenue and Forecast to 2028 (US$ Million)
Table 206. Saudi Arabia Biopharmaceuticals Market, by Recombinant Proteins – Revenue and Forecast to 2028 (US$ Million)
Table 207. Saudi Arabia Biopharmaceuticals Market, by Recombinant Hormones – Revenue and Forecast to 2028 (US$ Million)
Table 208. Saudi Arabia Biopharmaceuticals Market, by Recombinant Enzymes – Revenue and Forecast to 2028 (US$ Million)
Table 209. Saudi Arabia Biopharmaceuticals Market, by Cell & Gene Therapies – Revenue and Forecast to 2028 (US$ Million)
Table 210. Saudi Arabia Biopharmaceuticals Market, by Application – Revenue and Forecast to 2028 (US$ Million)
Table 211. South Africa Biopharmaceuticals Market, by Product Type – Revenue and Forecast to 2028 (US$ Million)
Table 212. South Africa Biopharmaceuticals Market, by Recombinant Vaccines – Revenue and Forecast to 2028 (US$ Million)
Table 213. South Africa Biopharmaceuticals Market, by Conventional Vaccines – Revenue and Forecast to 2028 (US$ Million)
Table 214. South Africa Biopharmaceuticals Market, by Recombinant Growth Factors – Revenue and Forecast to 2028 (US$ Million)
Table 215. South Africa Biopharmaceuticals Market, by Purified Proteins – Revenue and Forecast to 2028 (US$ Million)
Table 216. South Africa Biopharmaceuticals Market, by Recombinant Proteins – Revenue and Forecast to 2028 (US$ Million)
Table 217. South Africa Biopharmaceuticals Market, by Recombinant Hormones – Revenue and Forecast to 2028 (US$ Million)
Table 218. South Africa Biopharmaceuticals Market, by Recombinant Enzymes – Revenue and Forecast to 2028 (US$ Million)
Table 219. South Africa Biopharmaceuticals Market, by Cell & Gene Therapies – Revenue and Forecast to 2028 (US$ Million)
Table 220. South Africa Biopharmaceuticals Market, by Application – Revenue and Forecast to 2028 (US$ Million)
Table 221. Rest of Middle East & Africa Biopharmaceuticals Market, by Product Type – Revenue and Forecast to 2028 (US$ Million)
Table 222. Rest of Middle East & Africa Biopharmaceuticals Market, by Recombinant Vaccines – Revenue and Forecast to 2028 (US$ Million)
Table 223. Rest of Middle East & Africa Biopharmaceuticals Market, by Conventional Vaccines – Revenue and Forecast to 2028 (US$ Million)
Table 224. Rest of Middle East & Africa Biopharmaceuticals Market, by Recombinant Growth Factors – Revenue and Forecast to 2028 (US$ Million)
Table 225. Rest of Middle East & Africa Biopharmaceuticals Market, by Purified Proteins – Revenue and Forecast to 2028 (US$ Million)
Table 226. Rest of Middle East & Africa Biopharmaceuticals Market, by Recombinant Proteins – Revenue and Forecast to 2028 (US$ Million)
Table 227. Rest of Middle East & Africa Biopharmaceuticals Market, by Recombinant Hormones – Revenue and Forecast to 2028 (US$ Million)
Table 228. Rest of Middle East & Africa Biopharmaceuticals Market, by Recombinant Enzymes – Revenue and Forecast to 2028 (US$ Million)
Table 229. Rest of Middle East & Africa Biopharmaceuticals Market, by Cell & Gene Therapies – Revenue and Forecast to 2028 (US$ Million)
Table 230. Rest of Middle East & Africa Biopharmaceuticals Market, by Application – Revenue and Forecast to 2028 (US$ Million)
Table 231. South & Central America Biopharmaceuticals Market, by Product Type – Revenue and Forecast to 2028 (US$ Million)
Table 232. South & Central America Biopharmaceuticals Market, by Recombinant Vaccines – Revenue and Forecast to 2028 (US$ Million)
Table 233. South & Central America Biopharmaceuticals Market, by Conventional Vaccines – Revenue and Forecast to 2028 (US$ Million)
Table 234. South & Central America Biopharmaceuticals Market, by Recombinant Growth Factors – Revenue and Forecast to 2028 (US$ Million)
Table 235. South & Central America Biopharmaceuticals Market, by Purified Proteins – Revenue and Forecast to 2028 (US$ Million)
Table 236. South & Central America Biopharmaceuticals Market, by Recombinant Proteins – Revenue and Forecast to 2028 (US$ Million)
Table 237. South & Central America Biopharmaceuticals Market, by Recombinant Hormones – Revenue and Forecast to 2028 (US$ Million)
Table 238. South & Central America Biopharmaceuticals Market, by Recombinant Enzymes – Revenue and Forecast to 2028 (US$ Million)
Table 239. South & Central America Biopharmaceuticals Market, by Cell & Gene Therapies – Revenue and Forecast to 2028 (US$ Million)
Table 240. South & Central America Biopharmaceuticals Market, by Application – Revenue and Forecast to 2028 (US$ Million)
Table 241. Brazil Biopharmaceuticals Market, by Product Type – Revenue and Forecast to 2028 (US$ Million)
Table 242. Brazil Biopharmaceuticals Market, by Recombinant Vaccines – Revenue and Forecast to 2028 (US$ Million)
Table 243. Brazil Biopharmaceuticals Market, by Conventional Vaccines – Revenue and Forecast to 2028 (US$ Million)
Table 244. Brazil Biopharmaceuticals Market, by Recombinant Growth Factors – Revenue and Forecast to 2028 (US$ Million)
Table 245. Brazil Biopharmaceuticals Market, by Purified Proteins – Revenue and Forecast to 2028 (US$ Million)
Table 246. Brazil Biopharmaceuticals Market, by Recombinant Proteins – Revenue and Forecast to 2028 (US$ Million)
Table 247. Brazil Biopharmaceuticals Market, by Recombinant Hormones – Revenue and Forecast to 2028 (US$ Million)
Table 248. Brazil Biopharmaceuticals Market, by Recombinant Enzymes – Revenue and Forecast to 2028 (US$ Million)
Table 249. Brazil Biopharmaceuticals Market, by Cell & Gene Therapies – Revenue and Forecast to 2028 (US$ Million)
Table 250. Brazil Biopharmaceuticals Market, by Application – Revenue and Forecast to 2028 (US$ Million)
Table 251. Argentina Biopharmaceuticals Market, by Product Type – Revenue and Forecast to 2028 (US$ Million)
Table 252. Argentina Biopharmaceuticals Market, by Recombinant Vaccines – Revenue and Forecast to 2028 (US$ Million)
Table 253. Argentina Biopharmaceuticals Market, by Conventional Vaccines – Revenue and Forecast to 2028 (US$ Million)
Table 254. Argentina Biopharmaceuticals Market, by Recombinant Growth Factors – Revenue and Forecast to 2028 (US$ Million)
Table 255. Argentina Biopharmaceuticals Market, by Purified Proteins – Revenue and Forecast to 2028 (US$ Million)
Table 256. Argentina Biopharmaceuticals Market, by Recombinant Proteins – Revenue and Forecast to 2028 (US$ Million)
Table 257. Argentina Biopharmaceuticals Market, by Recombinant Hormones – Revenue and Forecast to 2028 (US$ Million)
Table 258. Argentina Biopharmaceuticals Market, by Recombinant Enzymes – Revenue and Forecast to 2028 (US$ Million)
Table 259. Argentina Biopharmaceuticals Market, by Cell & Gene Therapies – Revenue and Forecast to 2028 (US$ Million)
Table 260. Argentina Biopharmaceuticals Market, by Application – Revenue and Forecast to 2028 (US$ Million)
Table 261. Rest of South & Central America Biopharmaceuticals Market, by Product Type – Revenue and Forecast to 2028 (US$ Million)
Table 262. Rest of South & Central America Biopharmaceuticals Market, by Recombinant Vaccines – Revenue and Forecast to 2028 (US$ Million)
Table 263. Rest of South & Central America Biopharmaceuticals Market, by Conventional Vaccines – Revenue and Forecast to 2028 (US$ Million)
Table 264. Rest of South & Central America Biopharmaceuticals Market, by Recombinant Growth Factors – Revenue and Forecast to 2028 (US$ Million)
Table 265. Rest of South & Central America Biopharmaceuticals Market, by Purified Proteins – Revenue and Forecast to 2028 (US$ Million)
Table 266. Rest of South & Central America Biopharmaceuticals Market, by Recombinant Proteins – Revenue and Forecast to 2028 (US$ Million)
Table 267. Rest of South & Central America Biopharmaceuticals Market, by Recombinant Hormones – Revenue and Forecast to 2028 (US$ Million)
Table 268. Rest of South & Central America Biopharmaceuticals Market, by Recombinant Enzymes – Revenue and Forecast to 2028 (US$ Million)
Table 269. Rest of South & Central America Biopharmaceuticals Market, by Cell & Gene Therapies – Revenue and Forecast to 2028 (US$ Million)
Table 270. Rest of South & Central America Biopharmaceuticals Market, by Application – Revenue and Forecast to 2028 (US$ Million)
Table 271. Recent Organic Growth Strategies in Biopharmaceuticals Market
Table 272. Recent Inorganic Growth Strategies in the Biopharmaceuticals Market
Table 273. Glossary of Terms
LIST OF FIGURES
Figure 1. Biopharmaceuticals Market Segmentation
Figure 2. Biopharmaceuticals Market, by Region
Figure 3. Global Biopharmaceuticals Market Overview
Figure 4. Monoclonal Antibodies Segment Held Largest Share of Product Type Segment in Biopharmaceuticals Market
Figure 5. Asia Pacific Expected to Show Remarkable Growth During Forecast Period
Figure 6. Biopharmaceuticals Market, by Geography (US$ Million)
Figure 7. Global Biopharmaceuticals Market – Leading Country Markets (US$ Million)
Figure 8. Global Biopharmaceuticals Market – Industry Landscape
Figure 9. North America: PEST Analysis
Figure 10. Europe: PEST Analysis
Figure 11. Asia Pacific: PEST Analysis
Figure 12. Middle East & Africa: PEST Analysis
Figure 13. South & Central America: PEST Analysis
Figure 14. Experts’ Opinion
Figure 15. Biopharmaceuticals Market: Impact Analysis of Drivers and Restraints
Figure 16. Global Biopharmaceuticals Market – Revenue Forecast and Analysis – 2020–2028
Figure 17. Global Biopharmaceuticals Market, by Geography – Forecast and Analysis (2021–2028)
Figure 18. Market Positioning of Key Players in Biopharmaceuticals Market
Figure 19. Biopharmaceuticals Market Revenue Share, by Product Type 2021 & 2028 (%)
Figure 20. Monoclonal Antibodies: Biopharmaceuticals Market – Revenue and Forecast to 2028 (US$ Million)
Figure 21. Recombinant Vaccines: Biopharmaceuticals Market – Revenue and Forecast to 2028 (US$ Million)
Figure 22. Cancer Vaccine: Biopharmaceuticals Market – Revenue and Forecast to 2028 (US$ Million)
Figure 23. Malaria Vaccine: Biopharmaceuticals Market – Revenue and Forecast to 2028 (US$ Million)
Figure 24. Ebola Vaccine: Biopharmaceuticals Market – Revenue and Forecast to 2028 (US$ Million)
Figure 25. Hepatitis-B Vaccine: Biopharmaceuticals Market – Revenue and Forecast to 2028 (US$ Million)
Figure 26. Tetanus Vaccine: Biopharmaceuticals Market – Revenue and Forecast to 2028 (US$ Million)
Figure 27. Diphtheria Vaccine: Biopharmaceuticals Market – Revenue and Forecast to 2028 (US$ Million)
Figure 28. Cholera Vaccine: Biopharmaceuticals Market – Revenue and Forecast to 2028 (US$ Million)
Figure 29. Others: Biopharmaceuticals Market – Revenue and Forecast to 2028 (US$ Million)
Figure 30. Conventional Vaccines: Biopharmaceuticals Market – Revenue and Forecast to 2028 (US$ Million)
Figure 31. Polio Vaccine: Biopharmaceuticals Market – Revenue and Forecast to 2028 (US$ Million)
Figure 32. Pox Vaccine: Biopharmaceuticals Market – Revenue and Forecast to 2028 (US$ Million)
Figure 33. Other Conventional Vaccine: Biopharmaceuticals Market – Revenue and Forecast to 2028 (US$ Million)
Figure 34. Recombinant Growth Factors: Biopharmaceuticals Market – Revenue and Forecast to 2028 (US$ Million)
Figure 35. Erythropoietin: Biopharmaceuticals Market – Revenue and Forecast to 2028 (US$ Million)
Figure 36. Granulocyte Colony Stimulating Factor: Biopharmaceuticals Market – Revenue and Forecast to 2028 (US$ Million)
Figure 37. Purified Proteins: Biopharmaceuticals Market – Revenue and Forecast to 2028 (US$ Million)
Figure 38. Leukemia Inhibitory Factor (LIF): Biopharmaceuticals Market – Revenue and Forecast to 2028 (US$ Million)
Figure 39. P53 Protein: Biopharmaceuticals Market – Revenue and Forecast to 2028 (US$ Million)
Figure 40. P38 Protein: Biopharmaceuticals Market – Revenue and Forecast to 2028 (US$ Million)
Figure 41. Other Purified Proteins: Biopharmaceuticals Market – Revenue and Forecast to 2028 (US$ Million)
Figure 42. Recombinant Proteins: Biopharmaceuticals Market – Revenue and Forecast to 2028 (US$ Million)
Figure 43. Serum Albumin: Biopharmaceuticals Market – Revenue and Forecast to 2028 (US$ Million)
Figure 44. Amyloid Protein: Biopharmaceuticals Market – Revenue and Forecast to 2028 (US$ Million)
Figure 45. Defensin: Biopharmaceuticals Market – Revenue and Forecast to 2028 (US$ Million)
Figure 46. Transferrin: Biopharmaceuticals Market – Revenue and Forecast to 2028 (US$ Million)
Figure 47. Recombinant Hormones: Biopharmaceuticals Market – Revenue and Forecast to 2028 (US$ Million)
Figure 48. Recombinant Human Growth Hormones: Biopharmaceuticals Market – Revenue and Forecast to 2028 (US$ Million)
Figure 49. Recombinant Insulin: Biopharmaceuticals Market – Revenue and Forecast to 2028 (US$ Million)
Figure 50. Other Recombinant Hormones: Biopharmaceuticals Market – Revenue and Forecast to 2028 (US$ Million)
Figure 51. Recombinant Enzymes: Biopharmaceuticals Market – Revenue and Forecast to 2028 (US$ Million)
Figure 52. Enterokinase: Biopharmaceuticals Market – Revenue and Forecast to 2028 (US$ Million)
Figure 53. Cyclase: Biopharmaceuticals Market – Revenue and Forecast to 2028 (US$ Million)
Figure 54. Caspase: Biopharmaceuticals Market – Revenue and Forecast to 2028 (US$ Million)
Figure 55. Cathepsin: Biopharmaceuticals Market – Revenue and Forecast to 2028 (US$ Million)
Figure 56. Cell and Gene Therapies: Biopharmaceuticals Market – Revenue and Forecast to 2028 (US$ Million)
Figure 57. Allogenic Products: Biopharmaceuticals Market – Revenue and Forecast to 2028 (US$ Million)
Figure 58. Autologous Products: Biopharmaceuticals Market – Revenue and Forecast to 2028 (US$ Million)
Figure 59. Acellular Products: Biopharmaceuticals Market – Revenue and Forecast to 2028 (US$ Million)
Figure 60. Cytokines/Interferon/Interleukins: Biopharmaceuticals Market – Revenue and Forecast to 2028 (US$ Million)
Figure 61. Others (mRNA Based Therapeutics, etc.): Biopharmaceuticals Market – Revenue and Forecast to 2028 (US$ Million)
Figure 62. Global Biopharmaceuticals Market, by Application 2021 & 2028 (%)
Figure 63. Oncology: Biopharmaceuticals Market – Revenue and Forecast to 2028 (US$ Million)
Figure 64. Inflammatory and Infectious Diseases: Biopharmaceuticals Market – Revenue and Forecast to 2028 (US$ Million)
Figure 65. Autoimmune Disorders: Biopharmaceuticals Market – Revenue and Forecast to 2028 (US$ Million)
Figure 66. Metabolic Disorders: Biopharmaceuticals Market – Revenue and Forecast to 2028 (US$ Million)
Figure 67. Hormonal Disorders and Growth Failure: Biopharmaceuticals Market – Revenue and Forecast to 2028 (US$ Million)
Figure 68. Cardiovascular Diseases: Biopharmaceuticals Market – Revenue and Forecast to 2028 (US$ Million)
Figure 69. Neurological Diseases: Biopharmaceuticals Market – Revenue and Forecast to 2028 (US$ Million)
Figure 70. Other Therapeutic Applications: Biopharmaceuticals Market – Revenue and Forecast to 2028 (US$ Million)
Figure 71. North America: Biopharmaceuticals Market, by Key Country – Revenue (2021) (US$ Million)
Figure 72. North America Biopharmaceuticals Market – Revenue and Forecast to 2028 (US$ Million)
Figure 73. North America: Biopharmaceuticals Market, by Country, 2021 & 2028 (%)
Figure 74. United States: Biopharmaceuticals Market – Revenue and Forecast to 2028 (US$ Million)
Figure 75. Canada: Biopharmaceuticals Market – Revenue and Forecast to 2028 (US$ Million)
Figure 76. Mexico: Biopharmaceuticals Market – Revenue and Forecast to 2028 (US$ Million)
Figure 77. Europe: Biopharmaceuticals Market, by Key Country – Revenue (2021) (US$ Million)
Figure 78. Europe Biopharmaceuticals Market – Revenue and Forecast to 2028 (US$ Million)
Figure 79. Europe: Biopharmaceuticals Market, by Country, 2021 & 2028 (%)
Figure 80. United Kingdom: Biopharmaceuticals Market – Revenue and Forecast to 2028 (US$ Million)
Figure 81. Germany: Biopharmaceuticals Market – Revenue and Forecast to 2028 (US$ Million)
Figure 82. France: Biopharmaceuticals Market – Revenue and Forecast to 2028 (US$ Million)
Figure 83. Italy: Biopharmaceuticals Market – Revenue and Forecast to 2028 (US$ Million)
Figure 84. Spain: Biopharmaceuticals Market – Revenue and Forecast to 2028 (US$ Million)
Figure 85. Rest of Europe: Biopharmaceuticals Market – Revenue and Forecast to 2028 (US$ Million)
Figure 86. Asia Pacific: Biopharmaceuticals Market, by Key Country – Revenue (2021) (US$ Million)
Figure 87. Asia Pacific Biopharmaceuticals Market – Revenue and Forecast to 2028 (US$ Million)
Figure 88. China: Biopharmaceuticals Market – Revenue and Forecast to 2028 (US$ Million)
Figure 89. Japan: Biopharmaceuticals Market – Revenue and Forecast to 2028 (US$ Million)
Figure 90. India: Biopharmaceuticals Market – Revenue and Forecast to 2028 (US$ Million)
Figure 91. South Korea: Biopharmaceuticals Market – Revenue and Forecast to 2028 (US$ Million)
Figure 92. Australia: Biopharmaceuticals Market – Revenue and Forecast to 2028 (US$ Million)
Figure 93. Rest of Asia Pacific: Biopharmaceuticals Market – Revenue and Forecast to 2028 (US$ Million)
Figure 94. Middle East & Africa: Biopharmaceuticals Market, by Key Country – Revenue (2021) (US$ Million)
Figure 95. Middle East & Africa Biopharmaceuticals Market – Revenue and Forecast to 2028 (US$ Million)
Figure 96. UAE: Biopharmaceuticals Market – Revenue and Forecast to 2028 (US$ Million)
Figure 97. Saudi Arabia: Biopharmaceuticals Market – Revenue and Forecast to 2028 (US$ Million)
Figure 98. South Africa: Biopharmaceuticals Market – Revenue and Forecast to 2028 (US$ Million)
Figure 99. Rest of Middle East & Africa: Biopharmaceuticals Market – Revenue and Forecast to 2028 (US$ Million)
Figure 100. South & Central America: Biopharmaceuticals Market, by Key Country – Revenue (2021) (US$ Million)
Figure 101. South & Central America Biopharmaceuticals Market – Revenue and Forecast to 2028 (US$ Million)
Figure 102. South & Central America: Biopharmaceuticals Market, by Country, 2021 & 2028 (%)
Figure 103. Brazil: Biopharmaceuticals Market – Revenue and Forecast to 2028 (US$ Million)
Figure 104. Argentina: Biopharmaceuticals Market – Revenue and Forecast to 2028 (US$ Million)
Figure 105. Rest of South & Central America: Biopharmaceuticals Market – Revenue and Forecast to 2028 (US$ Million)
Figure 106. IMPACT OF COVID-19 PANDEMIC IN NORTH AMERICAN COUNTRY MARKETS
Figure 107. IMPACT OF COVID-19 PANDEMIC IN EUROPEAN COUNTRY MARKETS
Figure 108. IMPACT OF COVID-19 PANDEMIC IN ASIA PACIFIC COUNTRY MARKETS
Figure 109. IMPACT OF COVID-19 PANDEMIC IN MIDDLE EAST & AFRICA COUNTRY MARKETS
Figure 110. IMPACT OF COVID-19 PANDEMIC ON SOUTH & CENTRAL AMERICAN COUNTRY MARKETS
Figure 111. Growth Strategies in Biopharmaceuticals Market
The List of Companies - Biopharmaceuticals Market
- Amgen Inc.
- AbbVie Inc.
- Eli Lilly and Co
- Bristol-Myers Squibb Co
- Johnson & Johnson
- Thermo Fisher Scientific Inc
- AGC Biologics AS
- Lonza Group AG
- WuXi Biologics Inc
- Boehringer Ingelheim International GmbH.
The Insight Partners performs research in 4 major stages: Data Collection & Secondary Research, Primary Research, Data Analysis and Data Triangulation & Final Review.
- Data Collection and Secondary Research:
As a market research and consulting firm operating from a decade, we have published many reports and advised several clients across the globe. First step for any study will start with an assessment of currently available data and insights from existing reports. Further, historical and current market information is collected from Investor Presentations, Annual Reports, SEC Filings, etc., and other information related to company’s performance and market positioning are gathered from Paid Databases (Factiva, Hoovers, and Reuters) and various other publications available in public domain.
Several associations trade associates, technical forums, institutes, societies and organizations are accessed to gain technical as well as market related insights through their publications such as research papers, blogs and press releases related to the studies are referred to get cues about the market. Further, white papers, journals, magazines, and other news articles published in the last 3 years are scrutinized and analyzed to understand the current market trends.
- Primary Research:
The primarily interview analysis comprise of data obtained from industry participants interview and answers to survey questions gathered by in-house primary team.
For primary research, interviews are conducted with industry experts/CEOs/Marketing Managers/Sales Managers/VPs/Subject Matter Experts from both demand and supply side to get a 360-degree view of the market. The primary team conducts several interviews based on the complexity of the markets to understand the various market trends and dynamics which makes research more credible and precise.
A typical research interview fulfils the following functions:
- Provides first-hand information on the market size, market trends, growth trends, competitive landscape, and outlook
- Validates and strengthens in-house secondary research findings
- Develops the analysis team’s expertise and market understanding
Primary research involves email interactions and telephone interviews for each market, category, segment, and sub-segment across geographies. The participants who typically take part in such a process include, but are not limited to:
- Industry participants: VPs, business development managers, market intelligence managers and national sales managers
- Outside experts: Valuation experts, research analysts and key opinion leaders specializing in the electronics and semiconductor industry.
Below is the breakup of our primary respondents by company, designation, and region:
Once we receive the confirmation from primary research sources or primary respondents, we finalize the base year market estimation and forecast the data as per the macroeconomic and microeconomic factors assessed during data collection.
- Data Analysis:
Once data is validated through both secondary as well as primary respondents, we finalize the market estimations by hypothesis formulation and factor analysis at regional and country level.
- 3.1 Macro-Economic Factor Analysis:
We analyse macroeconomic indicators such the gross domestic product (GDP), increase in the demand for goods and services across industries, technological advancement, regional economic growth, governmental policies, the influence of COVID-19, PEST analysis, and other aspects. This analysis aids in setting benchmarks for various nations/regions and approximating market splits. Additionally, the general trend of the aforementioned components aid in determining the market's development possibilities.
- 3.2 Country Level Data:
Various factors that are especially aligned to the country are taken into account to determine the market size for a certain area and country, including the presence of vendors, such as headquarters and offices, the country's GDP, demand patterns, and industry growth. To comprehend the market dynamics for the nation, a number of growth variables, inhibitors, application areas, and current market trends are researched. The aforementioned elements aid in determining the country's overall market's growth potential.
- 3.3 Company Profile:
The “Table of Contents” is formulated by listing and analyzing more than 25 - 30 companies operating in the market ecosystem across geographies. However, we profile only 10 companies as a standard practice in our syndicate reports. These 10 companies comprise leading, emerging, and regional players. Nonetheless, our analysis is not restricted to the 10 listed companies, we also analyze other companies present in the market to develop a holistic view and understand the prevailing trends. The “Company Profiles” section in the report covers key facts, business description, products & services, financial information, SWOT analysis, and key developments. The financial information presented is extracted from the annual reports and official documents of the publicly listed companies. Upon collecting the information for the sections of respective companies, we verify them via various primary sources and then compile the data in respective company profiles. The company level information helps us in deriving the base number as well as in forecasting the market size.
- 3.4 Developing Base Number:
Aggregation of sales statistics (2020-2022) and macro-economic factor, and other secondary and primary research insights are utilized to arrive at base number and related market shares for 2022. The data gaps are identified in this step and relevant market data is analyzed, collected from paid primary interviews or databases. On finalizing the base year market size, forecasts are developed on the basis of macro-economic, industry and market growth factors and company level analysis.
- Data Triangulation and Final Review:
The market findings and base year market size calculations are validated from supply as well as demand side. Demand side validations are based on macro-economic factor analysis and benchmarks for respective regions and countries. In case of supply side validations, revenues of major companies are estimated (in case not available) based on industry benchmark, approximate number of employees, product portfolio, and primary interviews revenues are gathered. Further revenue from target product/service segment is assessed to avoid overshooting of market statistics. In case of heavy deviations between supply and demand side values, all thes steps are repeated to achieve synchronization.
We follow an iterative model, wherein we share our research findings with Subject Matter Experts (SME’s) and Key Opinion Leaders (KOLs) until consensus view of the market is not formulated – this model negates any drastic deviation in the opinions of experts. Only validated and universally acceptable research findings are quoted in our reports.
We have important check points that we use to validate our research findings – which we call – data triangulation, where we validate the information, we generate from secondary sources with primary interviews and then we re-validate with our internal data bases and Subject matter experts. This comprehensive model enables us to deliver high quality, reliable data in shortest possible time.
Get Free Sample For